

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|-----------|--|
| (51) International Patent Classification ⁶: A61K 31/215 | A1 | (11) International Publication Number: WO 97/41849 (43) International Publication Date: 13 November 1997 (13.11.97) |
| (21) International Application Number: PCT/US97/07525 (22) International Filing Date: 2 May 1997 (02.05.97) (30) Priority Data: 60/016,906 6 May 1996 (06.05.96) US (71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): COLACINO, Joseph, M. [US/US]; 9415 Moorings Boulevard, Indianapolis, IN 46256 (US). HORNBACK, William, J. [US/US]; 10063 Bent Tree Lane, Fishers, IN 46038 (US). MAULDIN, Scott, C. [US/US]; 5540 Snowberry Court, Indianapolis, IN 46221 (US). MUNROE, John, E. [US/US]; 5783 Rolling Pines Court, Indianapolis, IN 46220 (US). TANG, Joseph, Chiou-Chung [US/US]; 1512 Dorchester Place, Carmel, IN 46033 (US). (74) Agents: MCCLAIN, Janet, T. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). | | (81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| (54) Title: ANTI-VIRAL METHOD | | |
| (57) Abstract | | |
| <p>The present invention provides a method of inhibiting an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in a virus-infected cell, a cell susceptible of infection or a mammal in need thereof.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

- 1 -

ANTI-VIRAL METHOD

Influenza viruses cause an infectious disease for which there is no adequate therapeutic agent. The disadvantages of existing treatments include the onset of clinical resistance within thirty six hours and the ineffectiveness of the agents against influenza B. Killed influenza virus vaccines have been available for over sixty years. However, these vaccines have not lessened the morbidity, mortality or severe financial loss caused by this disease. It follows that an agent which treats or prevents an influenza infection or is effective at preventing the clinical symptoms associated with an influenza infection will result in a significant benefit to society.

Currently, the only compounds approved for the therapeutic and prophylactic treatment of influenza infections are the adamantanes: amantadine and rimantadine. These compounds inhibit influenza A by inhibiting the function of the M2 ion channel activity of the virus. Amantadine is a potent *in vitro* inhibitor of influenza A virus as demonstrated by standard antiviral assays such as the plaque reduction assay. Amantadine is effective in reducing the duration of fever and other systemic complaints including but not limited to myalgia (muscular ache) and fatigue when administered to individuals infected with influenza A within forty-eight hours of the onset of clinical symptoms. It has also been observed that amantadine results in a one hundred-fold decrease of virus titer in the nasal washes of human volunteers infected with wild-type influenza virus which correlates with a dramatic decrease in fever score. Thus, *in vitro* influenza inhibition is predictive of useful *in vivo* effects, i.e. a reduction of the clinical symptoms associated with the influenza infection.

The present invention derives from the fact that influenza is an enveloped virus which dictates that the virus envelope must be fused with the endosomal membrane of the host cell in order to initiate the process of introducing its genetic information into the cell. Because this process is common to all enveloped viruses, it is an attractive target for antiviral

chemotherapy. Examples of envelope viruses which are inhibited according to the present invention include influenza, bovine diarrheal, hepatitis C, tick borne encephalitis and the like. The fusion domain of the envelope glycoprotein of influenza, hemagglutinin (HA) has been well characterized. See, White J.M., Annu. Rev. Physiol. vol. 52, pages 675-697 (1990) which is herein incorporated by reference.

Influenza virus HA provides at least two distinct functions: 1) recognition of the host cell receptor, i.e., sialic acid residues on glycoconjugates, and 2) fusion of the viral envelope with the endosomal membrane. Both functions are essential for the propagation of influenza virus *in vitro* and *in vivo*. During viral maturation, monomeric HA is inserted into a lipid bilayer, post-translationally modified and oligomerized into a trimer of identical subunits (trimeric HA). The infectivity of the progeny virus is contingent upon a site-specific cleavage of HA by host cell protease(s). This cleavage results in the formation of two polypeptide chains, HA1 and HA2, which remain associated by non-covalent interactions as well as by an intermolecular and intramolecular disulfide bonds.

It has been established that influenza HA has two functionally relevant conformations. One conformation (Form A) exists as a metastable structure at neutral pH and mediates receptor recognition. Following receptor mediated binding to the host cell, the virus is transported to the endosomal compartment where it encounters an acidic environment. The low pH triggers a dramatic structural rearrangement of HA (Form A) which results in the formation of the other, more stable conformation of HA (Form B).


Form B of HA is required for fusion of the virus envelope with the endosomal membrane. It is the structural rearrangement from Form A to Form B of HA that allows the fusion domain of HA to directly interact with the endosomal membrane enabling the release of viral genetic information into the host cell cytoplasm. These considerations lend themselves to the development of a strategy for antiviral

- 3 -

intervention based on the abrogation of HA-mediated fusion of virus-host membranes.

The present invention relates to methods for using the compounds disclosed in the application for the treatment or prevention of viral infection and the resultant symptoms. These compounds, their pharmaceutically acceptable salts and the pharmaceutical compositions can be used alone or in combination with other antivirals, immunomodulators, antibiotics or vaccines.

The present invention relates to a method of treating or preventing a virus infection where the virus is an envelope virus that undergoes hemagglutinin-mediated fusion with the host cell which comprises administering to a virus infected cell, a cell susceptible of infection or a mammal in need thereof an effective amount of a compound of formula I:



I

wherein:

R is hydrogen or R and R⁶ combine to form a bond;

R⁰ and R¹ are independently hydrogen, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy(C₁-C₆ alkyl), sulfhydryl, sulfamyl, -SO₂-Cl, -S-C(O)-N(CH₃)₂, amino, C₁-C₄ alkylamino, di(C₁-C₄ alkyl)amino, C₁-C₄ alkylsulfonylamino, di(C₁-C₄ alkylsulfonyl)amino -X⁰-O-C(O)-C₁-C₄ alkyl, -O-(X¹)_i-X², -C(O)-X³, -N-C(O)-R² or -O-R³;

X⁰ is a bond or divalent(C₁-C₆ alkyl);

X¹ is an amino acid;

X² is hydrogen or an amino protecting group;


i is 1, 2 or 3;

- 4 -

X^3 is C_1 - C_6 alkyl, C_1 - C_6 alkoxy, halo(C_1 - C_6 alkyl), hydroxy(C_1 - C_6 alkyl) or phenyl;

R^2 is C_1 - C_4 alkyl, C_1 - C_4 alkoxy, halo(C_1 - C_4 alkyl), hydroxy(C_1 - C_4 alkyl), phenyl, p-methoxy-phenyl, p-fluoro-phenyl, naphthyl, pyridyl, piperidiny, thiazolyl, oxazolyl, thienyl, furyl, tetrahydrofuryl or cyclohexyl;

R^3 is C_1 - C_6 alkenyl, $-CH_2-R^{3a}$, $-C(O)-R^{3b}$, $-C(S)-R^{3c}$, $-C(CH_3)_2C(O)NH_2$, phenyl or a group of the formula:



R^{3a} is phenyl, p-fluorophenyl, pyridyl, pyrrolidiny, piperidiny, piperaziny, morpholiny, N-(C_1 - C_4 alkoxy carbonyl)piperidiny, N-(trifluoromethyl)-piperidiny, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, isooxazolyl, quinolyl, isoquinolyl, thienyl, furyl, tetrahydrothienyl, tetrahydrofuryl, cyclohexyl, cyclopentyl, cyclopropyl or naphthyl;

R^{3b} is pyrrolidiny, piperidiny, piperaziny, morpholiny, N-(C_1 - C_4 alkoxy carbonyl)piperidiny, N-(trifluoromethyl)piperidiny, benzyloxy, pyridylmethoxy, C_1 - C_6 alkoxy, halo(C_1 - C_4 alkoxy), amino, C_1 - C_4 alkylamino or di(C_1 - C_4 alkyl)amino;

R^{3c} is amino, C_1 - C_4 alkylamino or di(C_1 - C_4 alkyl)amino;

R^{3d} is oxygen, hydroximino, hydrazino or $=CHZ$;

Z is hydrogen, C_1 - C_4 alkyl, halogen, di(C_1 - C_4 alkyl)amino, C_1 - C_4 alkoxy carbonyl, carbamoyl(C_1 - C_4 alkyl), N-(C_1 - C_4 alkyl)carbamoyl or N,N-di(C_1 - C_4 alkyl)carbamoyl;

R^{3e} is hydrogen, nitro or trifluoromethyl;

X is a bond or $-(CH_2)-$;

R^4 is hydrogen, hydroxy, amino, C_1 - C_4 alkylamino, di(C_1 - C_4 alkyl)amino, C_1 - C_4 alkoxy, $=O$, $-O-S(CH_3)_2C(CH_3)_3$, C_2 - C_6 alkanoyloxy, N-(C_2 - C_6 alkanoyl)amino, $=N-R^5$ or R^4 and R^6 combine to form a bond;

- 5 -

R⁵ is hydroxy, amino, C₁-C₄ alkylamino, di(C₁-C₄ alkyl)amino, C₁-C₄ alkoxy, pyridylmethoxy, benzyloxy, piperazinyl, N-(methyl)piperazinyl or -O-CH₂-C(O)-R^{5a};

R^{5a} is hydroxy or C₁-C₄ alkoxy;

5 R⁶ is hydrogen, halo, C₁-C₄ alkyl or =O;

R⁷ is hydrogen or C₁-C₄ alkyl;

R⁸ is hydroxy, halo, C₁-C₆ alkoxy, pyrrolidinyl, piperidinyl, piperazinyl, 4-methyl-piperazinyl, morpholinyl or -N(R⁹)-R¹⁰;

10 R⁹ is hydrogen or methyl;

R¹⁰ is -(divalent C₁-C₆ alkyl)-R^{10a};

R^{10a} is pyridyl,

with the proviso that R⁶ cannot combine with both R⁴ and R to form a bond;

15 or a pharmaceutically acceptable salt thereof.

All temperatures stated herein are in degrees Celsius (°C). All units of measurement employed herein are in weight units except for liquids which are in volume units.

20 The term "halo" represents chloro, fluoro, bromo or iodo.

The term "C₁-C₆ alkyl" represents a straight or branched alkyl chain having from one to six carbon atoms. Typical C₁-C₆ alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl and the like. The term "C₁-C₆ alkyl" includes within its definition the term "C₁-C₄ alkyl."

30 The term "halo(C₁-C₆)alkyl" represents a straight or branched alkyl chain having from one to six carbon atoms with 1, 2 or 3 halogen atoms attached to it. Typical halo(C₁-C₆)alkyl groups include chloromethyl, 2-bromoethyl, 1-chloroisopropyl, 3-fluoropropyl, 2,3-dibromobutyl, 3-chloroisobutyl, iodo-t-butyl, trifluoromethyl and the like.

The term "hydroxy(C₁-C₆)alkyl" represents a straight or branched alkyl chain having from one to six carbon atoms with an hydroxy group attached to it. Typical hydroxy(C₁-C₆)alkyl groups include hydroxymethyl, 2-hydroxyethyl, 1-
5 hydroxyisopropyl, 2-hydroxypropyl, 2-hydroxybutyl, 3-hydroxyisobutyl, hydroxy-t-butyl, hydroxypentyl and the like.

The term "C₁-C₄ alkylamino" represents a straight or branched alkylamino chain having from one to four carbon atoms attached to an amino group. Typical C₁-C₄ alkyl-amino
10 groups include methylamino, ethylamino, propylamino, isopropylamino, butylamino, sec-butylamino and the like.

The term "di(C₁-C₄)alkylamino" represents a straight or branched dialkylamino chain having two alkyl chains, each having independently from one to four carbon atoms attached to a common amino group. Typical di(C₁-C₄)alkylamino groups
15 include dimethylamino, ethylmethylamino, methylisopropylamino, t-butylisopropylamino, di-t-butylamino and the like.

The term "C₁-C₆ alkoxy" represents a straight or branched alkyl chain having from one to six carbon atoms attached to an oxygen atom. Typical C₁-C₆ alkoxy groups
20 include methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy and the like. The term "C₁-C₆ alkoxy" includes within its definition the term "C₁-C₄ alkoxy".

The term "C₂-C₆ alkenyl" represents a straight or branched alkenyl chain having from two to six carbon atoms. Typical C₂-C₆ alkenyl groups include ethenyl, propenyl, isopropenyl, buten-2-yl, t-butenyl, penten-1-yl, hexen-3-yl, 3-methylpentenyl and the like.
25

The term "C₁-C₄ alkoxy-carbonyl" represents a straight or branched alkoxy chain having from one to four carbon atoms attached to a carbonyl moiety. Typical C₁-C₄ alkoxy-carbonyl groups include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, t-butoxycarbonyl and the like.
30

The term "carbamoyl(C₁-C₄)alkyl" represents a straight or branched alkyl chain having from one to four carbon atoms with a carbamoyl group attached to it. Typical carbamoyl(C₁-
35

C₄)alkyl groups include carbamoylmethyl, carbamoylethyl, carbamoylpropyl, carbamoylisopropyl, carbamoylbutyl and carbamoyl-t-butyl and the like.

The term "N-(C₁-C₄)alkylcarbamoyl" represents a straight or branched alkyl chain having from one to four carbon atoms attached to the nitrogen atom of a carbamoyl moiety. Typical N-(C₁-C₄ alkyl)carbamoyl groups include N-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl, N-isopropylcarbamoyl, N-butylcarbamoyl, N-t-butylcarbamoyl and the like.

The term "N,N-di(C₁-C₄ alkyl)carbamoyl" represents a straight or branched alkyl chain having a straight or branched C₁-C₄ alkyl chain attached to each of the nitrogen atoms on a carbamoyl moiety. Typical N-(C₁-C₄)alkylcarbamoyl groups include N,N-dimethylcarbamoyl, N-ethyl-N-methylcarbamoyl, N-propyl-N-butylcarbamoyl, N,N-diisopropylcarbamoyl, N-methyl-N-butylcarbamoyl and the like.

The term "C₁-C₄ alkylsulfonylamino" represents a straight or branched alkyl group having from one to four carbon atoms attached to a sulfonylamino moiety. Typical C₁-C₄ alkylsulfonylamino groups include methylsulfonyl-amino, ethylsulfonylamino, propylsulfonylamino, isopropylsulfonylamino, butylsulfonylamino, isobutylsulfonylamino, sec-butylsulfonylamino, and t-butylsulfonylamino.

The term "di(C₁-C₄ alkylsulfonyl)amino" represents two C₁-C₄ alkylsulfonyl moieties attached to an amino moiety. Typical di(C₁-C₄ alkylsulfonyl)amino groups include methylmethylsulfonylamino, ethylmethylsulfonylamino, propylethylsulfonylamino, isopropylmethylsulfonylamino, t-butylethylsulfonylamino, butylbutylsulfonylamino and the like.

The term "C₂-C₆ alkanoyl" represents a straight or branched alkyl chain having from one to five carbon atoms attached to a carbonyl moiety. Typical C₂-C₆ alkanoyl groups include ethanoyl, propanoyl, isopropanoyl, butanoyl, t-butanoyl, pentanoyl, hexanoyl, 3-methylpentanoyl and the like.

The term "C₂-C₆ alkanoyloxy" represents a straight or branched alkyl group having from one to five carbon atoms attached to a carbonyloxy moiety. Typical C₂-C₆ alkanoyloxy groups include ethanoyloxy, propanoyloxy, isopropanoyloxy, butanoyloxy, isobutanoyloxy, sec-butanoyloxy, t-butanoyloxy, pentanoyloxy and the like.

The term "C₂-C₆ alkanoylamino" represents a straight or branched alkyl group one to five carbon atoms attached to a carbonylamino moiety. Typical C₂-C₆ alkanoylamino groups include ethanoylamino, propanoylamino, isopropanoylamino, butanoyl-amino, isobutanoylamino, sec-butanoylamino, t-butanoylamino, pentanoylamino and the like.

As mentioned above, the invention includes the pharmaceutically acceptable salts of the compounds defined by formula I. Although generally neutral, a compound of this invention can possess a sufficiently acidic, a sufficiently basic, or both functional groups, and accordingly react with any of a number of inorganic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.

The term "pharmaceutically acceptable salt" as used herein, refers to salts of the compounds of the above formula which are substantially non-toxic to living organisms. Typical pharmaceutically acceptable salts include those salts prepared by reaction of the compounds of the present invention with a mineral or organic acid or an inorganic base. Such salts are known as acid addition and base addition salts.

Acids commonly employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid and the like, and organic acids such as p-toluenesulfonic, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.

Examples of such pharmaceutically acceptable salts are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate,

metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, γ -hydroxybutyrate, glycollate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate and the like. Preferred pharmaceutically acceptable acid addition salts are those formed with mineral acids such as hydrochloric acid and hydrobromic acid, and those formed with organic acids such as maleic acid and methanesulfonic acid.

Base addition salts include those derived from inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like. Such bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate, and the like. The potassium and sodium salt forms are particularly preferred.

It should be recognized that the particular counterion forming a part of any salt of this invention is not of a critical nature, so long as the salt as a whole is pharmacologically acceptable and as long as the counterion does not contribute undesired qualities to the salt as a whole.

The term "amino-protecting group" as used in the specification refers to substituents of the amino group commonly employed to block or protect the amino functionality while reacting other functional groups on the compound. Examples of such amino-protecting groups include formyl, trityl, phthalimido, trichloroacetyl, chloroacetyl, bromoacetyl, iodoacetyl groups, or urethane-type blocking


- 10 -

groups such as benzyloxycarbonyl, 4-phenylbenzyloxycarbonyl, 2-methylbenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 4-fluorobenzyloxycarbonyl, 4-chlorobenzyloxycarbonyl, 3-chlorobenzyloxycarbonyl, 2-chlorobenzyloxycarbonyl, 2,4-dichlorobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 3-bromobenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-cyanobenzyloxycarbonyl, t-butoxycarbonyl, 2-(4-xenyl)isopropoxycarbonyl, 1,1-diphenyleth-1-yloxycarbonyl, 1,1-diphenylprop-1-yloxycarbonyl, 2-phenylprop-2-yloxycarbonyl, 2-(p-toluy1)-prop-2-yloxycarbonyl, cyclopentanyloxycarbonyl, 1-methylcyclopentanyloxycarbonyl, cyclohexanyloxycarbonyl, 1-methylcyclohexanyloxycarbonyl, 2-methylcyclohexanyloxycarbonyl, 2-(4-toluy1sulfonyl)-ethoxycarbonyl, 2-(methy1sulfonyl)ethoxycarbonyl, 2-(triphenylphosphino)-ethoxycarbonyl, fluorenylmethoxycarbonyl ("Fmoc"), 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, 1-(trimethylsilylmethyl)prop-1-enyloxycarbonyl, 5-benzisoxaly1methoxycarbonyl, 4-acetoxybenzyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-ethynyl-2-propoxycarbonyl, cyclopropylmethoxycarbonyl, 4-(decyloxy)benzyloxycarbonyl, isobornyloxycarbonyl, 1-piperidyloxycarbonyl and the like; benzoylmethylsulfonyl, 2-nitrophenylsulfenyl, diphenylphosphine oxide and like amino-protecting groups. The species of amino-protecting group employed is not critical so long as the derivatized amino group is stable to the condition of subsequent reaction(s) on other positions of the intermediate molecule and can be selectively removed at the appropriate point without disrupting the remainder of the molecule including any other amino-protecting group(s). Preferred amino-protecting groups are t-butoxycarbonyl (t-Boc), allyloxycarbonyl and benzyloxycarbonyl (CbZ). Further examples of groups referred to by the above terms are described by J. W. Barton, "Protective Groups in Organic Chemistry", J. G. W. McOmie, Ed., Plenum Press, New York, N.Y., 1973, Chapter 2, and T. W. Greene, "Protective Groups in Organic Synthesis", John Wiley and sons, New York, N.Y., 1981, Chapter 7.

- 11 -


The term "carboxy-protecting group" as used in the specification refers to substituents of the carboxy group commonly employed to block or protect the carboxy functionality while reacting other functional groups on the compound. Examples of such carboxy-protecting groups include methyl, p-nitrobenzyl, p-methylbenzyl, p-methoxy-benzyl, 3,4-dimethoxybenzyl, 2,4-dimethoxybenzyl, 2,4,6-trimethoxybenzyl, 2,4,6-trimethylbenzyl, pentamethylbenzyl, 3,4-methylenedioxybenzyl, benzhydryl, 4,4'-dimethoxy-benzhydryl, 2,2',4,4'-tetramethoxybenzhydryl, t-butyl, t-amyl, trityl, 4-methoxytrityl, 4,4'-dimethoxytrityl, 4,4',4''-trimethoxytrityl, 2-phenylprop-2-yl, trimethylsilyl, t-butyldimethylsilyl, phenacyl, 2,2,2-trichloroethyl, β -(dibutylmethylsilyl)ethyl, p-toluenesulfonylethyl, 4-nitrobenzylsulfonylethyl, allyl, cinnamyl, 1-(trimethylsilylmethyl)prop-1-en-3-yl and like moieties. Preferred carboxy-protecting groups are allyl, benzyl and t-butyl. Further examples of these groups are found in E. Haslam, "Protective Groups in Organic Chemistry", J.G.W. McOmie, Ed.; Plenum Press, New York, N.Y., 1973, Chapter 5, and T.W. Greene, "Protective Groups in Organic Synthesis", John Wiley and Sons, New York, N.Y., 1981, Chapter 5.

The compounds used in the present invention have at least two asymmetric centers as denoted by the asterisks in the formula below:




The following stereoisomers are preferred:


- 12 -




I-1




I-2



I-3




I-4




I-5

- 13 -



I-6



I-7

Preferred compounds used in the claimed method are those compounds of formula I where:

5 R^0 is hydrogen, hydroxy, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy(C_1 - C_6 alkyl), $-X^0-O-C(O)-C_1-C_4$ alkyl, $-O-(X^1)_i-X^2$, $-C(O)-X^3$ or $-O-R^3$;

10 R^1 is hydrogen, hydroxy, C_1 - C_6 alkoxy, sulfhydryl, sulfamyl, $-SO_2-Cl$, amino, di(C_1 - C_4 alkylsulfonyl)amino $-C(O)-X^3$, $-N-C(O)-R^2$ or $-O-R^3$;

X^0 is a bond or divalent(C_1 - C_6 alkyl);

X^1 is an amino acid;


X^2 is hydrogen or an amino protecting group;

i is 1 or 2;


15 X^3 is C_1 - C_6 alkyl;

R^2 is hydroxy(C_1 - C_4 alkyl);

R^3 is C_1 - C_6 alkenyl, $-CH_2-R^{3a}$, $-C(O)-R^{3b}$, $-C(S)-R^{3c}$, $-C(CH_3)_2C(O)NH_2$ or a group of the formula:



or



- 14 -

R^{3a} is phenyl, p-fluorophenyl, pyridyl, piperidinyl, piperazinyl or morpholinyl;

R^{3b} is piperidinyl, piperazinyl, morpholinyl, N-(C₁-C₄ alkoxy carbonyl)piperidinyl, N-(trifluoromethyl)piperidinyl, halo(C₁-C₄ alkoxy) or di(C₁-C₄ alkyl)amino;

R^{3c} is di(C₁-C₄ alkyl)amino;

R^{3d} is oxygen or hydroximino;

R^{3e} is hydrogen, nitro or trifluoromethyl;

X is a bond;

R⁴ is hydrogen, hydroxy, amino, =O, C₂-C₆ alkanoyloxy, =N-R⁵, -OSi(CH₃)₂ or R⁴ and R⁶ combine to form a bond;

R⁵ is hydroxy, amino, di(C₁-C₄ alkyl)amino, C₁-C₄ alkoxy, pyridylmethoxy, N-(methyl)piperazinyl or -O-CH₂-C(O)-R^{5a};

R⁶ is hydrogen, chloro, bromo, methyl or =O;

R⁷ is hydrogen or methyl;

R⁸ is hydroxy, chloro, methoxy, 4-methylpiperazinyl or -N(R⁹)-R¹⁰;

R⁹ is hydrogen;

R¹⁰ is -CH₂-R^{10a}; and

R^{10a} is pyridyl;

or a pharmaceutically acceptable salt thereof.

Of these compounds, more preferred are those compounds of formula I where:

R⁰ is hydrogen, hydroxy, C₁-C₆ alkoxy, -O-(X¹)_i-X², -X⁰-O-C(O)-C₁-C₄ alkyl or -O-R³;

R¹ is hydrogen, hydroxy, C₁-C₆ alkoxy or -O-R³;

X⁰ is a bond;

X¹ is an amino acid;

X² is hydrogen or an amino protecting group;

i is 1 or 2;

R³ is C₁-C₆ alkenyl, -CH₂-R^{3a} or -C(O)-R^{3b};

R^{3a} is p-fluorophenyl or pyridyl;

R^{3b} is piperidinyl;

R⁴ is hydrogen, hydroxy, =O or =N-R⁵;

R⁵ is hydroxy, dimethylamino or N-(methyl)piperazinyl;

- 15 -

R⁶ is hydrogen, bromo or =O;

R⁷ is methyl; and

R⁸ is methoxy;

or a pharmaceutically acceptable salt thereof.

5

Of these compounds, even more preferred are those compounds of formula I where:

R is hydrogen;

R⁰ is hydrogen, hydroxy, C₁-C₄ alkoxy, -O-(X¹)_i-X²,

10 -O-C(O)methyl or -O-R³;

R¹ is hydrogen, hydroxy, C₁-C₄ alkoxy or -O-R³;

X¹ is glycine, alanine or valine;

X² is hydrogen, t-butoxycarbonyl or benzyloxycarbonyl;

R⁴ is =O or =N-R⁵;

15 R⁵ is hydroxy;


R⁶ is hydrogen;

or a pharmaceutically acceptable salt thereof.

The compounds of formula I may be prepared according to procedures known in the art. For example, the following Reaction Schemes may be used, alone or in combination to provide the desired compounds. Once a reaction is complete, the intermediate compound may be isolated by procedures well-known in the art; for example, the compound may be
25 crystallized and then collected by filtration, or the reaction solvent may be removed by extraction, evaporation or decantation. The intermediate compound may be further purified, if desired, by common techniques such as crystallization or chromatography over solid supports such as
30 silica gel or alumina, before carrying out the next step of the reaction scheme.


The compounds of formula I where R⁴ is =O or =N-R may be prepared according to the procedures shown below in Reaction
35 Scheme I.

- 16 -

Reaction Scheme I

10

- 17 -



where Reactions I.4A and 4B represent alternative reactions
 5 that follow Reaction I.3 and Reaction I.4C is an alternative
 reaction following Reaction I.2.

Reaction scheme I is accomplished by carrying out
 reactions 1-4 in sequential order. Reaction I.1 is carried
 out by oxidizing a compound of formula IA, for example, by
 10 reaction with chromium trioxide in an acetic acid/water
 mixture, to provide the corresponding ketone. The chromium
 trioxide is generally employed in an amount ranging from
 equimolar proportions to about a 4 molar excess relative to
 the compound of formula IA, preferably in about a 2-4 molar
 15 excess. The acetic acid/water mixture is generally a 10:1 to
 a 2:1 mixture of acetic acid to water, preferably about 4:1.
 The reaction is generally substantially complete after about
 1 to 10 hours when conducted at a temperature of from about
 23°C to about 60°C. The reaction is preferably conducted at
 20 a temperature of from about 23°C to about 30°C for about 5 to
 10 hours.

In Reaction I.2, the ketone obtained from Reaction I.1
 is reacted with bromine in a suitable solvent such as diethyl
 ether, tetrahydrofuran or dimethoxyethane, to provide a

- 18 -

mixture of bromoketones which are then separated using standard separation techniques such as chromatography. These isomerically pure bromoketones are then used to prepare various isomerically pure compounds of formula I. The
5 bromine is generally employed in an amount ranging from about equimolar proportions to about a 2 molar excess relative to the ketone reactant, preferably in about a 1-1.5 molar excess. Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction and the
10 reactants are sufficiently solubilized to effect the desired reaction. The reaction is generally substantially complete after about 1 to 3 hours when conducted at a temperature of from about 23°C to about 30°C. The reaction is preferably conducted at room temperature for about 1 to 1.5 hours.

15 Alternatively, the ketone obtained from Reaction I.1 is reacted with a silylating agent in the presence of a base in a suitable solvent such as methylene chloride, diethyl ether or tetrahydrofuran to provide the corresponding silylated enol ether. Preferred bases include 2,6-lutidine and
20 collidine. A preferred silylating agent is t-butyldimethylsilyl trifluoromethanesulfonate. The silylating agent is generally employed in an amount ranging from about equimolar proportions to about a 2 molar excess relative to the ketone reactant, preferably in about a 1-1.5 molar
25 excess. Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction and the reactants are sufficiently solubilized to effect the desired reaction. The reaction is generally substantially complete after about 30 minutes to 2 hours when conducted at a
30 temperature of from about 0°C to about 50°C. The reaction is preferably conducted at a temperature of from about 10°C to about 25°C for about 30 minutes to about 1 hour.

The silylated enol ether is then reacted with bromine substantially as described above with the exception that the
35 reaction is carried out in the presence of acetic acid. Typical solvents suitable for use in this reaction include any organic solvent such as methylene chloride, diethyl ether

or tetrahydrofuran. Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction and the reactants are sufficiently solubilized to effect the desired reaction.

5 In Reaction I.3, the bromoketone is reduced, for example by reaction with zinc dust and sodium acetate in glacial acetic acid, to provide the corresponding ketones. The zinc is generally employed in an amount ranging from about
10 equimolar proportions to about a 4 molar excess relative to the ketone reactant, preferably in about a 1.5-3 molar excess. The sodium acetate is generally employed in an amount ranging from about 0.6 molar equivalents to about 1.2 molar equivalents relative to the ketone reactant. The
15 reaction is generally substantially complete after about 1 to 10 hours when conducted at a temperature of from about 60°C to the reflux temperature of the mixture. The reaction is preferably conducted at reflux temperature for about 1 to 2 hours.

20 Alternatively, hydroxylamine hydrochloride is reacted with sodium acetate in a suitable solvent such as ethanol. The sodium acetate is generally employed in an amount ranging from about 1.1 molar equivalents to about a 50 molar excess relative to the hydroxylamine. The reaction is generally
25 substantially complete after about 1 to 72 hours when conducted at a temperature of from about 25°C to about 80°C. The reaction is preferably conducted at a temperature in the range of from about 25°C to about 30°C for about 5 to 24 hours.

30 In Reaction I.4A, the ketone obtained from Reaction I.3 is reacted with hydroxylamine hydrochloride in a mixture of methanol, water and acetic acid to provide the desired oxime compound. The hydroxylamine hydrochloride is generally
35 employed in an amount ranging from about equimolar proportions to about a 4 molar excess relative to the ketone reactant, preferably in about a 1.3-3 molar excess. The ratio of methanol to water to acetic acid is generally 10-20:1:0.1, preferably 15:1:0.1 (by volume?). The reaction is


- 20 -

generally substantially complete after about 1 hour to about 2 days when conducted at a temperature of from about 40°C to the reflux temperature of the mixture. The reaction is preferably conducted at reflux temperature for about 1 to 6 hours.

In Reaction I.4B, the ketone obtained from Reaction I.3 is reacted with an hydrazine hydrochloride such as 1-amino-4-methylpiperazine, 1,1-dimethylhydrazine or hydrazine in the presence of a base in an inert solvent at a temperature of from about 25°C to 80°C for 2 to 24 hours. Typical bases include sodium acetate, potassium hydroxide, triethylamine and the like. Suitable solvents include ethanol, isopropanol and dimethylformamide. Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction and the reactants are sufficiently solubilized to effect the desired reaction.

In Reaction I.4C, the compounds obtained from Reaction I.2 where R is hydrogen may be eliminated by reacting the bromo ketone reactant with a base such as sodium methoxide in methanol, sodium ethoxide in ethanol, or triethylamine to provide the unsaturated compounds of formula I where R and R⁶ are combined to form a bond. The base is generally employed in about a 2-4 molar excess relative to the bromo ketone reactant, preferably in about a 3 molar excess. The reaction is generally substantially complete after about 3 to 9 hours when conducted at a temperature of from about 40°C to the reflux temperature of the mixture. The reaction is preferably conducted at reflux temperature 3 to 5 hours.

The phenyl moiety of the compounds of formula I prepared above may be substituted according to Reaction Scheme II, as follows.

Reaction Scheme II

where $R^{0'}$ and $R^{1'}$ are independently hydrogen or $-C(O)CH_3$; and $R^{0''}$ and $R^{1''}$ are independently hydrogen or hydroxy.

In Reaction II.1, the compound of formula I where R^0 and R^1 are each hydrogen is subjected to a Friedel-Crafts acylation by reacting the compound of formula I with an acid halide, in the presence of a catalyst in an inert solvent such as carbon disulfide. The acid halide is generally employed in an amount ranging from about equimolar proportions to about a 1.5 molar excess relative to the compound of formula I, preferably in about a 1.1-1.3 molar excess. Preferred acid halides include acetyl chloride, acetyl bromide or the like. Preferred catalysts include aluminum trichloride, aluminum tribromide or the like. Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction and the reactants are sufficiently solubilized to effect the desired reaction. The reaction is generally substantially complete after about 1 to 10 hours when conducted at a temperature of from about 50°C to the reflux temperature of the mixture. The reaction

- 22 -

is preferably conducted at reflux temperature for about 1 to 2 hours.

In Reaction II.2, the acylated compound of formula I obtained from Reaction II.1 is oxidized to provide the corresponding phenol in a two step reaction. First, the acyl moiety is reacted with a peracid in the presence of an acid catalyst in an inert solvent such as dimethoxyethane to provide the corresponding ester which is then reacted with sodium bicarbonate in an alcohol/water mixture to provide the desired phenol.

The peracid is generally employed in an amount ranging from about equimolar proportions to about a 2 molar excess relative to the acyl moiety, preferably in about a 1-1.3 molar excess. The amount of catalyst typically employed is in the range of 0.005-0.04 equivalents relative to the acyl moiety. A preferred peracid is metachloro-peroxybenzoic acid. A preferred catalyst is p-toluenesulfonic acid. Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction and the reactants are sufficiently solubilized to effect the desired reaction. The reaction is generally substantially complete after about 1 to 10 hours when conducted at a temperature of from about 50°C to the reflux temperature of the mixture. The reaction is preferably conducted at reflux temperature for about 1 to 3 hours.

The resultant ester is typically refluxed with a base in a methanol/water mixture for about 1 to 7 hours to provide the desired phenol compound. Preferred bases include sodium bicarbonate, sodium carbonate, sodium hydroxide or potassium hydroxide or the like. The base is generally employed in an excess, for example from about a 1 molar excess to about a 6 molar excess relative to the ester moiety, preferably in about a 2-5 molar excess.

The phenol compounds obtained from Reaction Scheme II may be used to prepare various substituted compounds of formula I, as described below.

- 23 -

For example, the hydroxy moiety may be alkylated by reacting the phenol compound with a suitable alkylating agent in the presence of a base in an inert solvent. Examples of bases include triethylamine, diisopropyl ethylamine, sodium hydride and potassium carbonate. Typical solvents include methylene chloride, tetrahydrofuran, dimethylformamide and the like. Solvent choice is not critical so long as the reactants are sufficiently solubilized to effect the desired reaction. Suitable alkylating agents include iodomethane, allyl iodide, p-fluorophenyl bromide, 3-bromomethyl-pyridine and 2-fluorobenzophenone and the like. The reaction is generally substantially complete after about 1 to 20 hours when conducted at a temperature of from about 0°C to 170°C. The reaction is preferably conducted at a temperature of from about 25°C to about 80°C for about 4 to 16 hours.

Alternatively, the hydroxy moiety may be alkylated by reacting the phenol with an alcohol in the presence of triphenylphosphine and a suitable activating agent in an inert solvent, such as tetrahydrofuran or ethylene glycol dimethyl ether. Examples of suitable activating agents include diethyl azodicarboxylate, dimethyl azodicarboxylate, diisopropyl azodicarboxylate and the like. Examples of alcohols include 3-pyridyl carbinol, N-t-butoxycarbonyl-3-piperidinemethanol and the like. The reaction is generally substantially complete after about 0.5 to 2 hours when conducted at a temperature of from about 0°C to 85°C. The reaction is preferably conducted at a temperature of from about 25°C to about 70°C for about 30 minutes to 1 hour.

The hydroxy moiety may be converted to an ester or a carbonate by reacting the phenol with an acylating agent in the presence of a base in an inert solvent, such as methylene chloride, tetrahydrofuran or dimethylformamide. Typical bases include triethylamine, diisopropyl ethylamine, sodium hydride and the like. Typical acylating agents include N-(t-butoxycarbonyl)-4-chlorocarbonyl piperidine, 2,2,2-trichloroethyl chloroformate, N-(t-butoxycarbonyl)-

hydroxybenzotriazole amino esters. The reaction is generally substantially complete after about 1 to 20 hours when conducted at a temperature of from about 0°C to 60°C. The reaction is preferably conducted at a temperature of from about 10°C to about 25°C for about 1 to 5 hours.

The hydroxy moiety may be converted to the corresponding aniline in a three step reaction. First, the phenol is reacted with a suitably substituted amide such as 2-methyl-2-bromo-propanamide in the presence of a base such as sodium hydride or triethylamine in an inert solvent, such as dioxane or tetrahydrofuran at a temperature of 25°C to 100°C to provide the corresponding amido-ether. This amido-ether is then reacted with sodium hydride in an inert solvent such as dimethylformamide, 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidone or a mixture thereof at temperatures ranging from 25°C to 145°C to provide the rearranged amido-alcohol. Finally, the amido-alcohol is reacted with an acid, such as hydrochloric acid in dioxane at 50°C to 100°C to provide the desired aniline.

The aniline may be converted to the corresponding sulfonamide by reacting the aniline with a sulfonyl chloride such as methanesulfonyl chloride or isopropylsulfonyl chloride in the presence of a base, such as triethylamine, diisopropyl ethylamine or sodium hydride at a temperature of from about 0°C to 50°C in an inert solvent, such as methylene chloride, tetrahydrofuran or dimethylformamide.

The hydroxy moiety may be converted to a thiophenol in a three step reaction. First the phenol is reacted with a thio-carbamoyl (for example dimethylthiocarbamoyl chloride) in the presence of a base in an suitable solvent, such as water or dimethylformamide at a temperature ranging from 25°C to 50°C for 1 to 3 hours to provide the oxo-thiocarbamate. Typical bases include potassium hydroxide, triethylamine and the like. The oxo-thiocarbamate is converted to the corresponding thio-oxocarbamate compound by isolating and heating the neat solid to its melting point. Finally, the thio-oxocarbamate is reacted with a base, such as potassium

- 25 -

hydroxide or sodium hydroxide in an alcoholic solvent, such as methanol or ethanol at a temperature of 20°C to 80°C for 20 minutes to 1 hour to provide the corresponding thiophenol.


5 The thiophenol may be converted to the corresponding sulfonamides by reacting the thiophenol with an oxidizing agent (for example, potassium nitrate) in an inert solvent such as acetonitrile, followed by the addition of a chlorinating agent (for example, sulfuryl chloride) at temperatures ranging from 0°C to 25°C to provide a mixture of
10 sulfonyl chlorides which are separable using standard chromatographic techniques. These sulfonyl chlorides may be converted to the desired sulfonamides by reaction with an appropriately substituted amine such as ammonium hydroxide, methylamine, isopropylamine or benzylamine at a temperature
15 of from about 0°C to 40°C in an inert solvent such as tetrahydrofuran.

The hydroxy moiety may be converted to the corresponding amino esters by reacting the phenol with an amino protected amino acid in the presence of a coupling reagent and a
20 catalyst in an inert solvent such as diethyl ether, tetrahydrofuran or methylene chloride. Preferred amino protecting groups include t-butoxycarbonyl or benzyloxycarbonyl. The amino reactant is generally employed in equimolar proportions to a slight excess (1.3 equivalents)
25 relative to the phenol reactant in the presence of an equimolar quantity to a slight excess (1.5 equivalents) of the coupling reagent. Typical coupling agents include dicyclohexylcarbodiimide (DCC), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, benzotriazol-1-yloxy-
30 tris(dimethylamino)phosphonium hexafluorophosphate (BOP), N,N'-diethylcarbodiimide, carbonyldiimidazole, bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-Cl) or N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) and the like. Preferred coupling agents include DCC and BOP.
35 Typical catalysts include DMAP and 4-pyrrolopyridine. The reaction is substantially complete in 1 to 10 hours when

- 26 -


carried out at a temperature of from about -30°C to about 35°C, preferably from about 0°C to about 25°C.

The starting materials used in the procedures detailed above may be obtained commercially or prepared according to procedures known in the art. For example, methyl O-methylpodocarpate having the following stereochemistry may be obtained from Aldrich Chemical Company:



In addition, the compound(s) of formula IA, below may be prepared substantially in accordance with the procedure detailed in Ohta and Ohmuri, Chem. Pharm. Bull. (Tokyo), vol 5, page 91 (1957). The isomeric mix of compounds may be separated using standard separation techniques. Preferably, these isomers are obtained using the bromination methodology described above in Reaction Scheme I.

The compound(s) of formula IA may also be used to prepare other isomers using the procedure detailed in Pelletier et al., Tetr. Lett. page 4179 (1971). For example, heating the compound(s) of formula IA in a high boiling point solvent such as triethylene glycol dimethylether (triglyme) results in a compound of formula IB as follows:



- 27 -

The resultant mixture of isomers is then separated using standard procedures such as recrystallization or column chromatography or may be subjected to the bromination methodology described above in Reaction Scheme I.

5

The following Preparations and Examples further illustrate specific aspects of the present invention. It is to be understood, however, that these examples are included for illustrative purposes only and are not intended to limit the scope of the invention in any respect and should not be so construed.

10

Preparation 1

N-t-Butoxycarbonyl-4-carboxy-piperidine

15

To a solution of 1.0 g (7.74 mmol) of 4-carboxy-piperidine in 40 ml of a 1:1 water/dioxane mixture, was added 3.2 g (23.2 mmol) of potassium carbonate (K_2CO_3) followed by 2.1 ml (9.3 mmol) of di(t-butyl)dicarbonate (BOC_2O). After 2 hours, the mixture was diluted with methylene chloride (CH_2Cl_2). The resulting layers were separated and the organic layer was dried over sodium sulfate (Na_2SO_4), filtered and concentrated in vacuo. The crude material was recrystallized from a 3:1 hot EtOAc/hexanes (EtOAc/hexanes) mixture. Yield: 1.52 g (86%).

20

Preparation 2

N-t-Butoxycarbonyl-3-hydroxymethyl-piperidine

To a mixture of 5.0 g (43.4 mmol) of 3-hydroxymethyl-piperidine in 200 ml of CH_2Cl_2 , was added 6.05 ml (43.4 mmol) of triethylamine (Et_3N), followed by 9.8 ml (43.4 mmol) of (BOC_2O). The reaction mixture was stirred for 1 hour at room temperature and then washed with 75 ml of a 0.1N hydrochloric acid solution (HCl), dried over Na_2SO_4 , filtered and then concentrated in vacuo.

30

Yield: 7.1 g (76%).

35

- 28 -

Preparation 32-Bromo-2-methyl-propanamide


To a cold (0°C) solution of 11 ml (89 mmol) of 2-bromo-2-methyl-propionyl bromide in 25 ml of hexane, was added 24 ml of concentrated ammonium hydroxide (NH₄OH), slowly. The reaction mixture was stirred for 20 minutes resulting in the formation of a white precipitate. This precipitate was isolated by filtration, washed three times with water (H₂O) and then dried in vacuo to provide 9.1 g of a white solid which was redissolved in 600 ml of hot chloroform (CHCl₃) and filtered immediately. The filtrate was combined with 2100 ml of hexane and cooled overnight.
Yield: 6.1 g of crystals (41%).

Example 1A. Methyl O-methyl podocarpate

The compound is prepared from podocarpic acid according to the method of Shaw, JOC, vol. 39, p. 1968, (1974), herein incorporated by reference.

¹H NMR (300 MHz, CDCl₃): δ 6.98 (d, J=8Hz, 1H); 6.83 (d, J=4Hz, 1H); 6.70 (dd, J=4,8Hz, 1H); 3.78 (s, 3H); 3.67 (s, 3H); 2.80 (m, 2H); 2.25 (m, 3H); 2.0 (m, 2H); 1.6 (m, 2H); 1.42 (m, 1H); 1.30 (s, 3H); 1.12 (m, 1H) and 1.05 (s, 3H).
MS: m/e 288 (M⁺).

B.



To a solution of 2.0 g (6.62 mmol) of the compound of Example 1A in 10 ml of 1,1,2 trichloroethane, was added 1.0 ml (7.0 mmol) of iodotrimethylsilane. The reaction mixture was heated to 70°C, reacted for 10 minutes, cooled, diluted with 150 ml of a 3:1 hexane/diethyl ether (hexane/Et₂O)


- 29 -

mixture and then washed with a saturated sodium bicarbonate solution (NaHCO_3), dried over Na_2SO_4 , filtered and concentrated in vacuo.

Yield: 1.51 g of a light tan solid (83%).

5 ^1H NMR (300 MHz, CDCl_3): δ 6.9 (d, $J=8\text{Hz}$, 1H); 6.72 (d, $J=4\text{Hz}$, 1H); 6.58 (dd, $J=4,8\text{Hz}$, 1H); 4.55 (s, 1H); 3.63 (s, 3H); 2.75 (m, 2H); 2.20 (m, 3H); 1.95 (m, 2H); 1.57 (m, 2H); 1.4 (m, 1H); 1.25 (s, 3H); 1.08 (m, 1H) and 1.01 (s, 3H).
MS: m/e 274 (M^+).

10




The compound was prepared substantially in accordance with the procedure detailed in Example 1B, using 1.0 g (3.31 mmol) of the compound of Example 1A, 1.0 ml (7.0 mmol) of
15 iodotrimethylsilane and 5 ml of 1,1,2-trichloroethane, with the exception that the saturated NaHCO_3 wash was acidified to pH 2. The desired compound was then extracted with CH_2Cl_2 , and the extracts were dried over Na_2SO_4 , filtered and then concentrated in vacuo to provide 100 mg of a white solid
20 (11%).

^1H NMR (300 MHz, CDCl_3): δ 6.93 (d, $J=8\text{Hz}$, 1H); 6.73 (d, $J=4\text{Hz}$, 1H); 6.6 (dd, $J=4,8\text{Hz}$, 1H); 2.78 (m, 2H); 2.22 (m, 3H); 2.03 (m, 2H); 1.58 (m, 2H); 1.40 (m, 1H); 1.35 (s, 3H); 1.15 (s, 3H) and 1.10 (m, 1H).

25 Note: 780 mg of the compound of Example 1B was recovered.

- 30 -

Example 2


To a solution of 100 mg (0.35 mmol) of the compound of
Example 1B in 2 ml of dimethylformamide (DMF), was added 62
mg (0.45 mmol) of K_2CO_3 , followed by 42 μ l (0.45 mmol) of
isopropyl bromide. The reaction mixture was stirred for 2
hours at room temperature and then combined with an
additional 180 mg (1.3 mmol) of K_2CO_3 and 130 μ l (1.38 mmol)
of isopropyl bromide. This mixture was stirred for 24 hours
and then diluted with a 1:1 hexane/ Et_2O mixture. The
resultant layers were separated and the organic layer was
washed sequentially with H_2O and 0.1N HCl, dried over Na_2SO_4 ,
filtered and then concentrated in vacuo to provide an oily
residue which was purified using flash chromatography (SiO_2 ,
eluent of 5% EtOAc in hexane).

Yield: 51 mg.

1H NMR (300 MHz, $CDCl_3$): δ 6.95 (d, $J=8Hz$, 1H); 6.8 (d,
 $J=4Hz$, 1H); 6.65 (dd, $J=4,8Hz$, 1H); 4.47 (m, 1H); 3.64 (s,
3H); 2.78 (m, 2H); 2.22 (m, 3H); 1.97 (m, 2H); 1.58 (m, 2H);
1.40 (m, 1H); 1.32 (d, $J=6Hz$, 3H); 1.28 (d, $J=6Hz$, 3H); 1.10
(m, 1H) and 1.07 (s, 3H).

The compounds described in Examples 3-5 were prepared
substantially in accordance with the procedure detailed in
Example 2, using the shown starting materials.


- 31 -

Example 3

100 mg (0.35 mmol) of the compound of Example 1B, 242 mg
5 (1.75 mmol) of K₂CO₃ and 169 μ l (1.40 mmol) of allylbromide in
2 ml of DMF.

Yield: 75 mg (65%).

¹H NMR (300 MHz, CDCl₃): δ 6.97 (d, J=8Hz, 1H); 6.83 (d,
J=4Hz, 1H); 6.68 (dd, J=4, 8Hz, 1H); 6.07 (m, 1H); 5.35 (m,
10 2H); 4.50 (m, 2H); 3.68 (s, 3H); 2.78 (m, 2H); 2.23 (m, 3H);
1.98 (m, 2H); 1.58 (m, 2H); 1.40 (m, 1H); 1.28 (s, 3H); 1.10
(m, 1H) and 1.03 (s, 3H).


Example 4

100 mg (0.35 mmol) of the compound of Example 1B, 93 mg
20 (0.67 mmol) of K₂CO₃ and 81 μ l (0.68 mmol) of 4-fluorobenzyl
chloride in 2 ml of DMF.

Yield: 87 mg (63%).

¹H NMR (300 MHz, CDCl₃): δ 7.4 (m, 2H); 7.08 (m, 2H); 6.98
(d, J=8Hz, 1H); 6.88 (d, J=4Hz, 1H); 6.74 (dd, J=4, 8Hz, 1H);
4.98 (s, 2H); 3.68 (s, 3H); 2.78 (m, 2H); 2.23 (m, 3H); 1.96
(m, 2H); 1.58 (m, 2H); 1.40 (m, 1H); 1.28 (s, 3H); 1.10 (m,
25 1H) and 1.03 (s, 3H).


- 32 -

Example 5

5 100 mg (0.35 mmol) of the compound of Example 1B, 180 mg (1.30 mmol) of K_2CO_3 and 107 mg (0.65 mmol) of 2-picolyl chloride hydrochloride in 2 ml of DMF.

Yield: 35 mg (26%).

10 1H NMR (300 MHz, $CDCl_3$): δ 8.58 (d, $J=6Hz$, 1H); 7.70 (m, 1H); 7.52 (d, $J=6Hz$, 1H); 7.20 (m, 1H); 6.95 (d, $J=8Hz$, 1H); 6.89 (d, $J=4Hz$, 1H); 6.74 (dd, $J=4,8Hz$, 1H); 5.18 (s, 2H); 3.64 (s, 3H); 2.77 (m, 2H); 2.20 (m, 3H); 1.97 (m, 2H); 1.55 (m, 2H); 1.27 (s, 3H); 1.08 (m, 1H) and 1.0 (s, 3H).

Example 6

20 A solution of 6.58 g (65.04 mmol) of chromium trioxide in 70 ml of a 4:1 acetic acid ($AcOH$)/ H_2O mixture was added to a mixture of 7.0 g (23.15 mmol) of the compound in Example 1A in 70 ml of $AcOH$. The reaction mixture was stirred for 18 hours resulting in the precipitation of a solid. This solid was isolated by filtration, washed with H_2O , dried in vacuo, redissolved in 75 ml of hot isopropanol ($iPrOH$) and filtered hot. The filtrate was combined with 225 ml of H_2O and cooled

25

- 33 -

to 5°C for 16 hours to provide crystals which were isolated by filtration, washed with H₂O and dried in vacuo at 45°C.

Yield: 6.31 g (86%).

¹H NMR (300 MHz, CDCl₃): δ 8.04 (d, J=8Hz, 1H); 6.88 (d, J=4Hz, 1H); 6.82 (dd, J=8,4Hz, 1H); 3.87 (s, 3H); 3.72 (s, 3H); 3.18 (m, 1H); 2.95 (m, 1H); 2.33 (m, 2H); 2.05 (m, 2H); 1.72 (m, 1H); 1.55 (m, 1H); 1.25 (s, 3H); 1.16 (m, 1H) and 1.11 (s, 3H).


MS: m/e 316 (M+).

Elemental Analysis for C₁₉H₂₄O₄:

Calcd: C, 72.13; H, 7.65;

Found: C, 72.15; H, 7.79.

Example 7



To a solution of 316 mg (1.0 mmol) of the compound of Example 6 in 3.0 ml of absolute ethanol (EtOH), was added 80 mg (1.15 mmol) of hydroxylamine hydrochloride followed by 94 mg (1.15 mmol) of sodium acetate (NaOAc). The reaction mixture was stirred for 65 hours at room temperature and then concentrated in vacuo to provide a solid which was partitioned between Et₂O and H₂O. The resultant layers were separated and the organic layer was dried over Na₂SO₄, filtered and concentrated in vacuo to provide a solid. This solid was redissolved in 0.5 ml of Et₂O and 8 ml of hot hexane and then cooled to 0°C resulting in the formation of crystals.

Yield: 282 mg (85%).

¹H NMR (300 MHz, CDCl₃): δ 8.0 (s, 1H); 7.88 (d, J=8Hz, 1H); 6.88 (d, J=4Hz, 1H); 6.78 (dd, J=4,8Hz, 1H); 3.82 (s, 3H);

- 34 -

3.74 (s, 3H); 3.45 (m, 1H); 3.07 (m, 1H); 2.30 (m, 2H); 2.02 (m, 1H); 1.72 (m, 2H); 1.57 (m, 1H); 1.35 (s, 3H); 1.13 (m, 1H) and 1.0 (s, 3H).


MS: m/e 331 (M+).

5 Elemental Analysis for $C_{19}H_{25}NO_4$:

Calcd: C, 68.86; H, 7.60; N, 4.23;

Found: C, 69.12; H, 7.69; N, 4.21.

Example 8



To a hot (100°C) solution of 426 mg (1.48 mmol) of the compound in Example 1B in 3.0 ml of collidine, was added 0.45 ml (2.66 mmol) of 2-fluorobenzophenone, 415 mg (3.0 mmol) of K₂CO₃ and 444 mg (5.58 mmol) of copper (II) oxide (CuO). The reaction mixture was then heated to 171°C and reacted for 16 hours. After cooling, the mixture was diluted with 50 ml of Et₂O, washed with 20 ml of 1N HCl, dried over Na₂SO₄, filtered and then concentrated in vacuo to provide a brown oil. This oil was purified using radial chromatography (4000 micron plate, gradient eluent of 75-100% CH₂Cl₂ in hexane).

Yield: 352 mg (51%).

¹H NMR (300MHz, CDCl₃): δ 7.82 (d, J=6Hz, 2H); 7.45 (m, 5H); 7.18 (m, 1H); 6.90 (m, 2H); 6.75 (m, 1H); 6.58 (m, 1H); 3.67 (s, 3H); 2.77 (m, 2H); 2.20 (m, 2H); 1.95 (m, 3H); 1.60 (m, 1H); 1.47 (m, 1H); 1.35 (m, 1H); 1.27 (s, 3H); 1.02 (m, 1H) and 0.95 (s, 3H).

MS: m/e 469 (M+).


- 35 -

Elemental Analysis for $C_{31}H_{32}O_4$:

Calcd: C, 79.46; H, 6.88;

Found: C, 79.53; H, 7.06.

5

Example 9

The compound was prepared substantially in accordance with the procedure detailed in Example 6, using 260 mg (0.56 mmol) of the compound of Example 8, 158 mg (1.56 mmol) of chromium trioxide in a 3.05 ml AcOH/0.34 ml H₂O mixture.

Yield: 231 mg (86%).


¹H NMR (300 MHz, CDCl₃): δ 7.90 (d, J=8Hz, 1H); 7.75 (m, 2H); 7.55 (m, 3H); 7.35 (m, 3H); 7.10 (d, J=8Hz, 1H); 6.72 (d, J=4Hz, 1H); 6.62 (dd, J=4.8Hz, 1H); 3.70 (s, 3H); 3.15 (m, 1H); 2.93 (m, 1H); 2.30 (m, 1H); 2.0 (m, 3H); 1.63 (m, 1H); 1.38 (m, 1H); 1.23 (s, 3H); 1.10 (m, 1H) and 1.0 (s, 3H).

MS: m/e 483 (M⁺).Elemental Analysis for $C_{31}H_{30}O_5$:

Calcd: C, 77.16; H, 6.27;

Found: C, 76.96; H, 6.29.

- 36 -

Example 10

The compound was obtained from the Bader chemical collection, Aldrich Chemical Company.


^1H NMR (300 MHz, CDCl_3): δ 8.38 (d, $J=4\text{Hz}$, 1H); 8.23 (dd, $J=4,8\text{Hz}$, 1H); 7.87 (d, $J=6\text{Hz}$, 2H); 7.60 (m, 1H); 7.48 (t, $J=6\text{Hz}$, 2H); 7.03 (d, $J=8\text{Hz}$, 1H); 6.85 (m, 2H); 6.68 (dd, $J=4,8\text{Hz}$, 1H); 3.64 (s, 3H); 2.80 (m, 2H); 2.22 (m, 2H); 1.98 (m, 3H); 1.55 (m, 2H); 1.33 (m, 1H); 1.26 (s, 3H); 1.07 (m, 1H) and 0.97 (s, 3H).

MS: m/e 513 (M^+).

Elemental Analysis for $\text{C}_{31}\text{H}_{31}\text{NO}_6$:

Calcd: C, 72.50; H, 6.08; N, 2.73

Found: C, 72.40; H, 6.11; N, 2.66.

Example 11

The compound was prepared substantially in accordance with the procedure detailed in Example 7, using 150 mg (0.311 mmol) of the compound of Example 9, 22 mg (0.311 mmol) of hydroxylamine hydrochloride and 26 mg (0.311 mmol) of NaOAc

- 37 -


in 3.0 ml of EtOH. The crude material was purified using radial chromatography (2000 micron plate, eluent of 5% EtOAc in CH₂Cl₂).

Yield: 138 mg (89%).

5 ¹H NMR (300 MHz, CDCl₃): δ 7.78 (m, 3H); 7.45 (m, 5H); 7.25 (m, 1H); 7.0 (d, J=8Hz, 1H); 6.75 (d, J=4Hz, 1H); 6.62 (dd, J=4,8Hz, 1H); 3.70 (s, 3H); 3.4 (m, 1H); 3.02 (m, 1H); 2.25 (m, 1H); 1.98 (m, 2H); 1.63 (m, 2H); 1.37 (m, 1H); 1.30 (s, 3H); 1.08 (m, 1H) and 0.92 (s, 3H).

10 MS: m/e 497 (M+).

B.



The compound was isolated from the reaction mixture described in Example 11A.


15 Yield: 5 mg.

¹H NMR (300 MHz, CDCl₃): δ 7.65 (d, J=8Hz, 1H); 7.50 (m, 2H); 7.30 (m, 6H); 7.02 (d, J=8Hz, 1H); 6.90 (d, J=4Hz, 1H); 6.78 (dd, J=4,8Hz, 1H); 3.69 (s, 3H); 3.4 (m, 1H); 3.02 (m, 1H); 2.2 (m, 2H); 1.95 (m, 1H); 1.63 (m, 2H); 1.42 (m, 1H); 1.30 (s, 3H); 1.08 (m, 1H) and 0.95 (s, 3H).

20

MS: m/e 512 (M+).

C.



- 38 -


The compound was isolated from the reaction mixture described in Example 11A.

Yield: 4 mg

^1H NMR (300 MHz, CDCl_3): δ 7.68 (t, $J=8\text{Hz}$, 1H); 7.50 (m, 1H); 7.30 (m, 5H); 6.85 (m, 3H); 6.58 (d, $J=4\text{Hz}$, 1H); 6.44 (dd, $J=4,8\text{Hz}$, 1H); 3.68 (s, 3H); 3.38 (m, 1H); 3.0 (m, 1H); 2.24 (m, 1H); 2.0 (m, 2H); 1.63 (m, 2H); 1.37 (m, 1H); 1.30 (s, 3H); 1.07 (m, 1H) and 0.92 (s, 3H).

MS: m/e 512 (M^+).

Example 12




The compound was prepared substantially in accordance with the procedure detailed in Example 8, using 100 mg (0.347 mmol) of the compound of Example 1B, 98 mg (0.423 mmol) of 2-bromobiphenyl, 97 mg (0.702 mmol) of K_2CO_3 and 70 mg (0.88 mmol) of CuO in 1.5 ml of collidine. The crude material was purified using column chromatography (eluent of 30% hexane in CH_2Cl_2).

Yield: 81 mg (53%).

^1H NMR (300 MHz, CDCl_3): δ 7.58 (m, 2H); 7.25 (m, 6H); 6.95 (m, 2H); 7.88 (d, $J=4\text{Hz}$, 1H); 6.70 (dd, $J=4,8\text{Hz}$, 1H); 3.64 (s, 3H); 2.78 (m, 2H); 2.15 (m, 3H); 1.95 (m, 2H); 1.55 (m, 2H); 1.35 (m, 1H); 1.25 (s, 3H); 1.05 (m, 1H) and 0.97 (s, 3H).

MS: m/e 440 (M^+).

- 39 -


Example 13

The compound was prepared substantially in accordance with the procedure detailed in Example 8, using 500 mg (1.74 mmol) of the compound of Example 1B, 950 mg (3.54 mmol) of 2-fluoro-5-(trifluoromethyl)benzo-phenone, 500 mg (3.62 mmol) of K_2CO_3 , and 350 mg (4.35 mmol) of CuO in 8.0 ml collidine. The crude material was purified using radial chromatography (4000 micron plate, eluent of 25% hexane in CH_2Cl_2).

Yield: 670 mg (72%).

1H NMR (300 MHz, $CDCl_3$): δ 7.84 (d, $J=8Hz$, 2H); 7.75 (m, 1H); 7.57 (m, 2H); 7.45 (t, $J=8Hz$, 2H); 6.97 (d, $J=8Hz$, 1H); 6.89 (d, $J=8Hz$, 1H); 6.80 (d, $J=4Hz$, 1H); 6.62 (dd, $J=4,8Hz$, 1H); 3.62 (s, 3H); 2.78 (m, 2H); 2.20 (m, 2H); 1.98 (m, 3H); 1.55 (m, 2H); 1.30 (m, 1H); 1.25 (s, 3H); 1.08 (m, 1H) and 0.96 (s, 3H).

MS: m/e 536 (M^+).

Example 14

- 40 -


The compound was prepared substantially in accordance with the procedure detailed in Example 6, using 75 mg (0.14 mmol) of the compound of Example 13, 40 mg (0.40 mmol) of chromium trioxide in a 0.85 ml AcOH/0.1 ml H₂O mixture.

Yield: 49 mg (64%).

¹H NMR (300 MHz, CDCl₃): δ 7.95 (d, J=6Hz, 1H); 7.77 (m, 3H); 7.58 (m, 1H); 7.42 (t, J=6Hz, 2H); 7.12 (d, J=8Hz, 1H); 6.80 (d, J=4Hz, 1H); 6.70 (dd, J=4,8Hz, 1H); 3.68 (s, 3H); 3.18 (m, 1H); 2.95 (m, 1H); 2.30 (m, 1H); 2.0 (m, 3H); 1.67 (m, 1H); 1.40 (m, 1H); 1.25 (s, 3H); 1.12 (m, 1H) and 1.03 (s, 3H).

MS: m/e 550 (M⁺).

Example 15




To a solution of 200 mg (0.694 mmol) of the compound of Example 1B in 5.0 ml of CH₂Cl₂, was added 0.372 ml (2.10 mmol) of diisopropylethylamine and 86 mg (0.70 mmol) of 4-dimethylamino pyridine followed by a mixture containing 480 mg (2.10 mmol) of the compound of Preparation 1, 0.207 ml (2.56 mmol) of pyridine and 0.170 ml (2.33 mmol) of thionyl chloride in 5.0 ml of CH₂Cl₂. The reaction mixture was stirred at room temperature for 30 minutes, diluted with CH₂Cl₂, washed sequentially with 1N HCl and a saturated NaHCO₃ solution, dried over Na₂SO₄, filtered and then concentrated in vacuo to provide a tan foam. This foam was purified using radial chromatography (2000 micron plate, gradient eluent of 10% hexane in CH₂Cl₂ to 25% EtOAc in CH₂Cl₂). Yield: 280 mg (81%).

- 41 -

^1H NMR (300 MHz, CDCl_3): δ 7.02 (d, $J=8\text{Hz}$, 1H); 6.90 (d, $J=4\text{Hz}$, 1H); 6.77 (dd, $J=4,8\text{Hz}$, 1H); 4.08 (m, 2H); 3.65 (s, 3H); 2.90 (m, 3H); 2.75 (m, 3H); 2.20 (m, 3H); 1.98 (m, 4H); 1.78 (m, 2H); 1.6 (m, 1H); 1.45 (s, 9H); 1.40 (m, 1H); 1.28 (s, 3H); 1.08 (m, 1H) and 1.0 (s, 3H).

MS: m/e 499 (M^+).

Example 16




To a solution of 250 mg (0.50 mmol) of the compound in Example 15 in 1.0 ml of CH_2Cl_2 , was added 0.160 ml (1.0 mmol) of triethylsilane and 1.0 ml of trifluoroacetic acid (CF_3COOH). The reaction mixture was stirred for 30 minutes at room temperature, diluted with 15 ml of acetonitrile (CH_3CN) and then concentrated in vacuo to provide 231 mg of a tan solid. Then, 200 mg of this solid was dissolved in 20 ml of CH_2Cl_2 , washed with a saturated NaHCO_3 solution, dried over Na_2SO_4 , filtered and concentrated in vacuo.

Yield: 170 mg (98%).

^1H NMR (300 MHz, CDCl_3): δ 7.02 (d, $J=8\text{Hz}$, 1H); 6.92 (d, $J=4\text{Hz}$, 1H); 6.78 (dd, $J=4,8\text{Hz}$, 1H); 3.63 (s, 3H); 3.17 (m, 2H); 2.75 (m, 5H); 2.20 (m, 3H); 1.98 (m, 4H); 1.75 (m, 2H); 1.58 (m, 2H); 1.40 (m, 1H); 1.27 (s, 3H); 1.08 (m, 1H) and 1.0 (s, 3H).


MS: m/e 400 (M^+).

- 42 -

Example 17

To a solution of 160 mg (0.4 mmol) of the free base of
the compound of Example 16 in 4.0 ml of a 3:1 Et₂O/hexane
mixture, was added 26 μ l (0.4 mmol) of methanesulfonic acid.
Yield: 198 mg of a solid (quantitative).

¹H NMR (300 MHz, CDCl₃): δ 8.43 (bs, 1H); 8.20 (bs, 1H); 6.75
(d, J=8Hz, 1H); 6.60 (d, J=4Hz, 1H); 6.45 (dd, J=4,8Hz, 1H);
3.55 (s, 3H); 3.20 (m, 2H); 2.90 (m, 2H); 2.58 (m, 3H); 2.30
(s, 3H); 2.10 (m, 3H); 1.93 (m, 4H); 1.65 (m, 2H); 1.47 (m,
2H); 1.24 (m, 1H); 1.17 (s, 3H); 1.08 (m, 1H) and 0.88 (s,
3H).

Example 18

To a solution of 160 mg (0.324 mmol) of the compound in
Example 17 in 3.0 ml CH₂Cl₂, was added 100 μ l (0.712 mmol) of
Et₃N and 50 μ l (0.356 mmol) of trifluoroacetic anhydride.
The reaction mixture was stirred for 15 minutes at room
temperature, diluted with 30 ml of EtOAc, sequentially washed
with 10 ml of 0.2N HCl, 10 ml of a saturated NaHCO₃ solution


- 43 -

and 10 ml brine, dried over NaSO_4 , filtered and then concentrated in vacuo.

Yield: 130 mg (81%).

^1H NMR (300 MHz, CDCl_3): δ 7.03 (d, $J=8\text{Hz}$, 1H); 6.91 (d, $J=4\text{Hz}$, 1H); 6.78 (dd, $J=4,8\text{Hz}$, 1H); 4.37 (m, 1H); 4.0 (m, 1H); 3.64 (s, 3H); 3.35 (m, 1H); 3.15 (m, 1H); 2.82 (m, 3H); 2.28 (m, 1H); 2.18 (m, 4H); 1.95 (m, 3H); 1.50 (m, 4H); 1.25 (s, 3H); 1.08 (m, 1H) and 1.0 (s, 3H).

Example 19




To a solution of 470 mg (1.63 mmol) of the compound of Example 1B in 12.0 ml of a 1:2 $\text{Et}_2\text{O}/\text{CH}_2\text{Cl}_2$ mixture, was added 0.237 ml (1.70 mmol) of Et_3N and 0.224 ml (1.63 mmol) of 2,2,2-trichloroethyl chloroformate. The reaction mixture was stirred at room temperature for 20 minutes, diluted with 50 ml of Et_2O , sequentially washed with 15 ml of H_2O , 15 ml of 0.2N HCl , 15 ml of NaCO_3 and 15 ml of brine, dried over Na_2SO_4 , filtered and then concentrated in vacuo to provide an oily residue. This residue was purified using flash chromatography (SiO_2 , eluent of 30% hexane in CH_2Cl_2).

Yield: 620 mg (82%).

^1H NMR (300MHz, CDCl_3): δ 7.08 (m, 2H); 6.93 (m, 1H); 4.87 (s, 2H); 3.67 (s, 3H); 2.90 (m, 1H); 2.78 (m, 1H); 2.23 (m, 3H); 2.00 (m, 2H); 1.58 (m, 2H); 1.42 (m, 1H); 1.30 (s, 3H); 1.12 (m, 1H) and 1.03 (s, 3H).

MS: m/e 463 (M^+).


- 44 -

Example 20

The compound was prepared substantially in accordance with the procedure detailed in Example 6, using 620 mg (1.33 mmol) of the compound of Example 19, 405 mg (4.0 mmol) of chromium trioxide in a 8.1 ml AcOH/0.9 ml H₂O.

Yield: 540 mg (85%).

¹H NMR (300MHz, CDCl₃): δ 8.02 (d, J=8Hz, 1H); 6.90 (d, J=4Hz, 1H); 6.80 (dd, J=4,8Hz, 1H); 5.02 (s, 2H); 3.70 (s, 3H); 3.18 (m, 1H); 2.83 (m, 1H); 2.30 (m, 2H); 2.03 (m, 2H); 1.70 (m, 1H); 1.50 (m, 1H); 1.25 (s, 3H); 1.10 (m, 1H) and 1.02 (s, 3H).

Example 21

To a solution of 5.3 g (11.1 mmol) of the compound of Example 20 in 90 ml of a 1:2 AcOH/EtOH mixture, was added 10.0 g (153 mmol) of zinc dust. The mixture was reacted for 5 minutes at 80°C and then cooled to room temperature, filtered and concentrated in vacuo to provide a solid. This solid was slurried in CH₂Cl₂ and filtered. The filtrate was dried in vacuo to provide a solid which was diluted with 100

- 45 -


ml of hot CHCl_3 and filtered into 700 ml of hexane. The compound was then crystallized from this solution.

Yield: 3.31 g (99%).

^1H NMR (300MHz, CDCl_3): δ 7.82 (d, $J=8\text{Hz}$, 1H); 6.80 (d, $J=4\text{Hz}$, 1H); 6.70 (dd, $J=4,8\text{Hz}$, 1H); 3.68 (s, 3H); 3.15 (m, 1H); 2.82 (m, 1H); 2.26 (m, 2H); 2.03 (m, 2H); 1.67 (m, 1H); 1.50 (m, 1H); 1.20 (s, 3H); 1.17 (m, 1H) and 1.08 (s, 3H).

MS: m/z 302 (M^+).

Example 22




The compound was prepared substantially in accordance with the procedure detailed in Example 15, using 440 mg (1.46 mmol) of the compound of Example 21, 0.645 ml (3.7 mmol) of diisopropylethylamine, 179 mg (1.46 mmol) of 4-dimethylaminopyridine, 845 mg (3.7 mmol) of the compound of Preparation 1, 0.365 ml (4.5 mmol) of pyridine and 0.300 (4.1 mmol) of thionyl chloride in 45 ml of CH_2Cl_2 .

Yield: 380 mg (51%).

^1H NMR (300MHz, CDCl_3): δ 8.08 (d, $J=8\text{Hz}$, 1H); 7.10 (d, $J=4\text{Hz}$, 1H); 7.0 (dd, $J=4,8\text{Hz}$, 1H); 4.08 (m, 2H); 3.71 (s, 3H); 3.22 (m, 1H); 2.95 (m, 3H); 2.72 (m, 1H); 2.30 (m, 2H); 2.05 (m, 4H); 1.75 (m, 3H) 1.47 (s, 9H); 1.26 (s, 3H); 1.16 (m, 1H) and 1.14 (s, 3H).


MS: m/e 513 (M^+).

- 46 -

Example 23

The compound was prepared substantially in accordance with the procedures detailed in Examples 16 and 17, using 160 mg (0.31 mmol) of the compound of Example 22, 0.1 ml (0.63 mmol) of triethylsilane, 2.0 ml of a 1:1 CF₃COOH/CH₂Cl₂ mixture and 20 μ l (0.31 mmol) of methanesulfonic acid. Yield: 153 mg (97%).

¹H NMR (300MHz, CDCl₃): δ 8.05 (m, 1H); 7.10 (m, 1H); 7.0 (m, 1H); 3.65 (s, 3H); 3.18 (m, 3H); 2.95 (m, 2H); 2.65 (m, 3H); 2.27 (bs, 3H); 2.05 (m, 5H); 1.75 (m, 3H); 1.50 (m, 1H); 1.23 (s, 3H); 1.18 (m, 1H) and 1.10 (s, 3H).

Example 24

To a solution of 250 mg (0.83 mmol) of the compound from Example 21 in 8.0 ml of tetrahydrofuran (THF), was added 85 μ l (0.87 mmol) of 3-pyridylcarbinol, 236 mg (0.9 mmol) of triphenylphosphine and 142 μ l (0.9 mmol) of diethyl azodicarboxylate. The reaction mixture was heated to 65°C and reacted for 10 minutes, cooled to room temperature and concentrated in vacuo to provide an oily residue which was

- 47 -


trituated in Et₂O and filtered. The filtrate was washed sequentially with H₂O and a 0.1N K₂CO₃ solution, dried over Na₂SO₄, filtered and concentrated in vacuo.

Yield: 198 mg of a tan solid (61%).

¹H NMR (300MHz, CDCl₃): δ 8.70 (s, 1H); 8.60 (d, J=4Hz, 1H); 8.05 (d, J=8Hz, 1H); 7.78 (d, J=8Hz, 1H); 7.35 (m, 1H); 6.95 (d, J=4Hz, 1H); 6.90 (dd, J=4,8Hz, 1H); 5.13 (s, 2H); 3.70 (s, 3H); 3.18 (m, 1H); 2.95 (m, 1H); 2.30 (m, 2H); 2.04 (m, 2H); 1.70 (m, 1H); 1.53 (m, 1H); 1.25 (s, 3H); 1.13 (m, 1H) and 1.10 (s, 3H).

MS: m/e 393 (M+).

Example 25




To a solution of 38 mg (0.097 mmol) of the compound from Example 24 in 2.2 ml of a 1:1:0.2 CH₃CN/Et₂O/hexane mixture, was added 0.1 ml of a HCl/CH₃CN solution (1.0 ml of concentrated HCl in 11.0 ml of CH₃CN) which resulted in the formation of a precipitate which was isolated by filtration.

Yield: 40 mg (96%).

¹H NMR (300MHz, CDCl₃): δ 8.80 (bs, 1H); 8.65 (s, 1H); 8.55 (d, J=4Hz, 1H); 7.98 (d, J=8Hz, 1H); 7.72 (d, J=8Hz, 1H); 7.30 (m, 1H); 6.90 (d, J=4Hz, 1H); 6.83 (dd, J=4,8Hz, 1H); 5.10 (s, 2H); 3.68 (s, 3H); 3.16 (m, 1H); 2.91 (m, 1H); 2.27 (m, 2H); 2.0 (m, 2H); 1.68 (m, 1H); 1.50 (m, 1H); 1.23 (s, 3H); 1.10 (m, 1H) and 1.03 (s, 3H).

MS: m/e 393 (M+ -HCl).

- 48 -


Example 26

The compounds were prepared substantially in accordance with the procedure detailed in Example 24, using 300 mg (0.992 mmol) of the compound of Example 21, 214 mg (0.992 mmol) of the compound of Preparation 2, 275 mg (1.05 mmol) of triphenylphosphine and 0.165 ml (1.05 mmol) of diethylazodicarboxylate in 9.0 ml of THF. The crude material was purified using radial chromatography (2000 micron plate, eluent of 5% EtOAc in CH₂Cl₂).

Yield: 477 mg (96%).

¹H NMR (300MHz, CDCl₃): δ 8.01 (d, J=8Hz, 1H); 6.84 (d, J=4Hz, 1H); 6.78 (dd, J=4,8Hz, 1H); 3.85 (m, 3H); 3.70 (s, 3H); 3.17 (m, 1H); 2.92 (m, 2H); 2.30 (m, 2H); 2.02 (m, 3H); 1.88 (m, 1H); 1.68 (m, 3H); 1.50 (m, 4H); 1.46 (s, 9H); 1.26 (s, 3H); 1.13 (m, 1H) and 1.10 (s, 3H).

MS: m/e 499 (M⁺).

Example 27

The compounds were prepared substantially in accordance with the procedures detailed in Examples 16 and 25, using 378 mg (0.76 mmol) of the compound of Example 26, 0.20 ml (1.26

- 49 -


mmol) of triethylsilane, 5.0 ml of a 2:3 $\text{CH}_2\text{Cl}_2/\text{CF}_3\text{COOH}$ mixture and 0.714 ml of a $\text{HCl}/\text{CH}_3\text{CN}$ solution (1.0 ml of concentrated HCl in 11.0 ml of CH_3CN).

Yield: 287 mg (87%).

^1H NMR (300MHz, CDCl_3): δ 9.02 (m, 2H); 7.80 (d, $J=8\text{Hz}$, 1H); 6.95 (s, 1H); 6.87 (d, $J=8\text{Hz}$, 1H); 3.97 (m, 2H); 3.60 (s, 3H); 3.22 (m, 1H); 3.03 (m, 1H); 3.74 (m, 3H); 2.20 (m, 5H); 1.75 (m, 5H); 1.35 (m, 2H); 1.18 (s, 3H); 1.13 (m, 1H) and 1.0 (s, 3H).

MS: m/e 399 ($\text{M}^+ - \text{HCl}$).

Example 28




To a solution of 1.2 g (3.97 mmol) of the compound of Example 21 in 50 ml of dioxane, was slowly added 210 mg (4.37 mmol) of a 50% dispersion of sodium hydride (NaH) in mineral oil, with stirring, followed by 663 mg (3.97 mmol) of the compound from Preparation 3. The mixture was heated to 100°C and reacted for 6 hours, then cooled and combined with 5.0 ml of 1N sodium hydroxide (NaOH), followed by 200 ml of EtOAc . The resultant layers were separated and the organic layer was dried over Na_2SO_4 , filtered and concentrated in vacuo.

Yield: 500 mg (32%).

^1H NMR (300MHz, CDCl_3): δ 7.98 (d, $J=8\text{Hz}$, 1H); 6.90 (d, $J=4\text{Hz}$, 1H); 6.83 (dd, $J=4,8\text{Hz}$, 1H); 6.40 (bs, 1H); 5.6 (bs, 1H); 3.70 (s, 3H); 3.18 (m, 1H); 2.95 (m, 1H); 2.28 (m, 2H); 2.02 (m, 2H); 1.70 (m, 1H); 1.61 (s, 3H); 1.58 (s, 3H); 1.48 (m, 1H); 1.25 (s, 3H); 1.13 (m, 1H) and 1.10 (s, 3H).

- 50 -


Example 29

To a solution of 480 mg (1.23 mmol) of the compound of
 5 Example 28 in a mixture of 15.0 ml DMF and 2.0 ml of 1,3-
 dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone, was added 66
 mg (1.36 mmol) of a 50% dispersion of NaH in mineral oil.
 The reaction mixture was refluxed for 5 minutes and then
 cooled to room temperature. To the mixture, was added 10 ml
 10 of a saturated NaHCO₃ solution followed by 100 ml of EtOAc.
 The resultant layers were separated and the organic layer was
 sequentially washed with H₂O and 0.2N HCl, dried over Na₂SO₄,
 filtered and concentrated in vacuo.

Yield: 380 mg of a tan solid (79%).

15 ¹H NMR (300MHz, CDCl₃): δ 8.90 (bs, 1H); 8.02 (d, J=8Hz, 1H);
 7.92 (d, J=4Hz, 1H); 7.32 (dd, J=4,8Hz, 1H); 3.70 (s, 3H);
 3.22 (m, 1H); 2.97 (m, 1H); 2.35 (m, 3H); 2.05 (m, 2H); 1.70
 (m, 1H); 1.57 (s; 6H); 1.52 (m, 1H); 1.25 (s, 3H); 1.15 (m,
 1H) and 1.12 (s, 3H).

20 MS: m/e 387 (M⁺).

Example 30

25 To a solution of 100 mg (0.257 mmol) of the compound of
 Example 29 in 5.0 ml of dioxane, was added 0.8 ml of 5N HCl.

- 51 -


The resultant mixture was heated to 100°C, reacted for 2 hours, cooled and then diluted with 50 ml of CH₂Cl₂. The resultant layers were separated and the organic layer was washed with a saturated NaHCO₃ solution dried over Na₂SO₄, filtered and concentrated in vacuo to provide a solid. This solid was purified using radial chromatography (1000 micron plate, eluent of 20% EtOAc in CH₂Cl₂).

Yield: 46 mg (60%).

¹H NMR (300MHz, CDCl₃): δ 7.90 (d, J=8Hz, 1H); 6.55 (m, 2H); 4.12 (bs, 2H); 3.70 (s, 3H); 3.15 (m, 1H); 2.90 (m, 1H); 2.27 (m, 2H); 2.02 (m, 2H); 1.67 (m, 1H); 1.50 (m, 1H); 1.22 (s, 3H); 1.12 (m, 1H) and 1.08 (s, 3H).

MS: m/e 301 (M+).

Example 31




To a solution of 25 mg (0.083 mmol) of the compound of Example 30 in 1.0 ml CH₂Cl₂, was slowly added 24 μl (0.172 mmol) of Et₃N and 13 μl (0.168 mmol) of methanesulfonyl chloride. The reaction mixture was diluted with EtOAc and washed sequentially with 0.2N HCl and a saturated NaHCO₃ solution, dried over Na₂SO₄, filtered and concentrated in vacuo.

Yield: 31 mg of a white solid (82%).

¹H NMR (300MHz, CDCl₃): δ 8.13 (d, J=8Hz, 1H); 7.4 (s, 1H); 7.30 (d, J=8Hz, 1H); 3.73 (s, 3H); 3.40 (s, 6H); 3.25 (m, 1H); 3.03 (m, 1H); 2.35 (m, 2H); 2.05 (m, 2H); 1.75 (m, 1H); 1.58 (m, 1H); 1.27 (s, 3H); 1.16 (m, 1H) and 1.15 (s, 3H).

- 52 -


Example 32

The compound was prepared substantially in accordance with the procedure detailed in Example 7, using 24 mg (0.053 mmol) of the compound of Example 31, 4.6 mg (0.066 mmol) of hydroxylamine hydrochloride and 5.4 mg (0.066 mmol) of NaOAc in 1.0 ml of EtOH. The crude material was purified using radial chromatography (1000 micron plate, eluent of 5% EtOAc in CH₂Cl₂).

Yield: 20 mg (80%).

¹H NMR (300MHz, CDCl₃): δ 8.0 (d, J=8Hz, 1H); 7.78 (s, 1H); 7.30 (d, J=4Hz, 1H); 7.18 (dd, J=4,8Hz, 1H); 3.72 (s, 3H); 3.42 (m, 1H); 3.40 (s, 6H); 3.10 (m, 1H); 2.32 (m, 2H); 2.02 (m, 1H); 1.73 (m, 2H); 1.55 (m, 1H); 1.33 (s, 3H); 1.13 (m, 1H) and 1.04 (s, 3H).

MS: m/e 472 (M⁺).

Example 33

To a solution of 1.5 g (4.96 mmol) of the compound of Example 21 and 278 mg (4.96 mmol) of potassium hydroxide (KOH) in 50 ml of H₂O, was added 817 mg (6.6 mmol) of dimethylthiocarbamoyl chloride. The reaction mixture was stirred rapidly for 15 minutes. The reaction mixture was

- 53 -


diluted with 100 ml of Et₂O and the organic phase was separated, dried over Na₂SO₄, filtered and concentrated in vacuo to provide an oily solid which was triturated in MeOH and then isolated by filtration.

5 Yield: 1.45 g (75%).

¹H NMR (300MHz, CDCl₃): δ 8.10 (d, J=8Hz, 1H); 7.13 (d, J=4Hz, 1H); 7.0 (dd, J=4,8Hz, 1H); 3.73 (s, 3H); 3.44 (s, 3H); 3.33 (s, 3H); 3.22 (m, 1H); 2.98 (m, 1H); 2.30 (m, 2H); 2.05 (m, 2H); 1.62 (m, 2H); 1.28 (s, 3H); 1.17 (m, 1H) and 1.14 (s, 3H).

10 MS: m/e 389 (M+).

Example 34




15 The compound was prepared by melting 300 mg (0.77 mmol) of the compound of Example 33 in a flask under nitrogen (N₂). The liquified residue was cooled to provide 300 mg of a glassy solid (quantitative).

20 ¹H NMR (300MHz, CDCl₃): δ 8.02 (d, J=8Hz, 1H); 7.58 (d, J=4Hz, 1H); 7.42 (dd, J=4, 8Hz, 1H); 3.70 (s, 3H); 3.22 (m, 1H); 3.04 (m, 7H); 2.35 (m, 2H); 2.05 (m, 2H); 1.70 (m, 1H); 1.57 (m, 1H); 1.27 (s, 3H); 1.16 (s, 3H) and 1.14 (m, 1H).

MS: m/e 390 (M+).

- 54 -


Example 35

To a solution of 480 mg (1.23 mmol) of the compound of
Example 34 in 15.0 ml of MeOH, was added 689 mg (12.3 mmol)
of KOH. The reaction mixture was refluxed for 20 minutes,
cooled to room temperature, and diluted with 80 ml of H₂O and
100 ml of Et₂O. The resulting layers were separated and the
aqueous layer was acidified with 4.0 ml of 5N HCl and then
combined with 100 ml of CH₂Cl₂. The resultant layers were
separated and the organic layer was dried over Na₂SO₄,
filtered and concentrated in vacuo.

Yield: 370 mg of a tan solid (94%).

¹H NMR (300MHz, CDCl₃): δ 7.90 (d, J=8Hz, 1H); 7.24 (d,
J=4Hz, 1H); 7.15 (d, J=8Hz, 1H); 3.70 (s, 3H); 3.60 (s, 1H);
3.18 (m, 1H); 2.95 (m, 1H); 2.32 (m, 2H); 2.02 (m, 2H); 1.72
(m, 1H); 1.50 (m, 1H); 1.25 (s, 3H); 1.14 (m, 1H) and 1.10
(s, 3H).

MS: m/e 318 (M⁺).

Example 36

To a 0°C solution of 320 mg (1.01 mmol) of the compound
of Example 35 in 20.0 ml of CH₃CN was added 253 mg (2.5 mmol)
of potassium nitrate (KNO₃) and 0.201 ml (2.5 mmol) of
sulfuryl chloride. The reaction mixture was stirred for 30

- 55 -

minutes at 0°C, diluted with 100 ml of Et₂O and washed with 30 ml of H₂O. The organic phase was separated, dried over Na₂SO₄, filtered and concentrated in vacuo to provide 280 mg of a crude yellow solid. This solid was purified using


5 radial chromatography (1000 micron plate, eluent of 2% EtOAc in CH₂Cl₂).

Yield: 105 mg (27%).

¹H NMR (300MHz, CDCl₃): δ 8.23 (d, J=8Hz, 1H); 8.08 (d, J=4Hz, 1H); 7.93 (dd, J=4,8Hz, 1H); 3.74 (s, 3H); 3.33 (m, 1H); 3.10 (m, 1H); 2.40 (m, 2H); 2.03 (m, 2H); 1.75 (m, 1H);

10 1.55 (m, 1H); 1.28 (s, 3H); 1.18 (s, 3H) and 1.16 (m, 1H).

MS: m/e 385 (M+).



15 The compound was isolated from the reaction mixture detailed in Example 36A.


Yield: 135 mg.

¹H NMR (300MHz, CDCl₃): δ 8.02 (m, 3H); 5.8 (d, J=8Hz, 1H); 3.75 (s, 3H); 2.35 (m, 3H); 1.85 (m, 3H); 1.53 (m, 1H); 1.50

20 (s, 3H) and 0.96 (s, 3H).

MS: m/e 418 (M+).

Example 37



25 To a solution of 100 mg (0.26 mmol) of the compound of Example 36A in 1.0 ml of THF, was added 60 μl (0.84 mmol) of


- 56 -

concentrated NH_4OH . The reaction mixture was diluted with 20.0 ml CH_2Cl_2 , washed with 10.0 ml H_2O , dried over Na_2SO_4 , filtered and concentrated in vacuo.

Yield: 90 mg (95%).

^1H NMR (300MHz, CDCl_3): δ 8.13 (d, $J=8\text{Hz}$, 1H); 8.0 (d, $J=4\text{Hz}$, 1H); 7.80 (dd, $J=4,8\text{Hz}$, 1H); 5.01 (s, 2H); 3.73 (s, 3H); 3.27 (m, 1H); 3.02 (m, 1H); 2.38 (m, 2H); 2.02 (m, 2H); 1.73 (m, 1H); 1.54 (m, 1H); 1.27 (s, 3H); 1.17 (m, 1H) and 1.13 (s, 3H).

Example 38




To a solution of 50 mg (0.157 mmol) of the compound of Example 35 in 15.0 ml of EtOH, was added 100 mg of Rainey nickel catalyst. The reaction mixture was shaken under hydrogen gas (60 psi) at room temperature for 3 hours and then filtered and concentrated in vacuo. The crude material was purified using radial chromatography (1000 micron plate, gradient eluent of 1-10% EtOAc in CH_2Cl_2).

Yield: 15 mg (33%).

^1H NMR (300MHz, CDCl_3): δ 8.03 (d, $J=8\text{Hz}$, 1H); 7.54 (t, $J=8\text{Hz}$, 1H); 7.40 (d, $J=8\text{Hz}$, 1H); 7.31 (d, $J=8\text{Hz}$, 1H); 3.72 (s, 3H); 3.22 (m, 1H); 3.0 (m, 1H); 2.37 (m, 2H); 2.03 (m, 2H); 1.73 (m, 1H); 1.55 (m, 1H); 1.26 (s, 3H); 1.14 (m, 1H) and 1.12 (s, 3H).

MS: m/e 286 (M^+).

- 57 -

Example 39

To a solution of 200 mg (0.632 mmol) of the compound of
Example 6 in 2.5 ml of EtOH was added 43 μ l (0.75 mmol) of
AcOH, and 396 μ l (5.2 mmol) of 1,1-dimethylhydrazine. The
reaction mixture was heated to 80°C and reacted for 4 hours,
concentrated in vacuo, diluted with Et₂O, washed with H₂O,
dried over Na₂SO₄, filtered and then concentrated in vacuo to
provide an oil. This oil was purified using radial
chromatography (2000 micron plate, eluent of 8% EtOAc in
CH₂Cl₂).

Yield: 145 mg (64%).


¹H NMR (300MHz, CDCl₃): δ 8.13 (d, J=8Hz, 1H); 6.81 (d,
J=4Hz, 1H); 6.74 (dd, J=4,8Hz, 1H); 3.81 (s, 3H); 3.71 (s,
3H); 3.61 (m, 1H); 2.78 (m, 1H); 2.60 (s, 6H); 2.28 (m, 2H);
1.72 (m, 2H); 1.47 (m, 1H); 1.32 (s, 3H); 1.12 (m, 1H) and
1.06 (s, 3H).

MS: m/e 358 (M⁺).

Elemental Analysis for C₂₁H₃₀N₂O₃:

Calcd: C, 70.36; H, 8.44; N, 7.81;

Found: C, 70.30; H, 7.91; N, 8.00.

Example 40

To a solution of 98 mg (0.273 mmol) of the compound from
Example 39 in 2.0 ml of Et₂O, was added 0.273 ml of a

solution containing 1.0 ml of concentrated HCl in 11.0 ml of CH₃CN. The reaction mixture was diluted with 10.0 ml of CH₃CN and then concentrated in vacuo to provide an oily residue. This residue was triturated with 3.0 ml of Et₂O and then isolated by filtration.

Yield: 105 mg (97%).

¹H NMR (300MHz, d₆-DMSO): δ 8.35 (bs, 1H); 8.10 (d, J=8Hz, 1H); 6.80 (d, J=4Hz, 1H); 6.71 (dd, J=4, 8Hz, 1H); 3.78 (s, 3H); 3.68 (s, 3H); 3.57 (m, 1H); 2.74 (m, 1H); 2.58 (s, 6H); 2.26 (m, 2H); 1.70 (m, 2H); 1.45 (m, 1H); 1.30 (s, 3H); 1.10 (m, 1H) and 1.02 (s, 3H).


MS: m/e 358 (M+-HCl).

Elemental Analysis for $C_{21}H_{31}N_2O_3Cl$:

Calc: C, 63.87; H, 7.91; N, 7.09; Cl, 8.98;

Found: C, 64.17; H, 8.07; N, 7.07; Cl, 9.08.

Example 41



To a solution of 2.0 g (6.32 mmol) of the compound from Example 6 in 20.0 ml of EtOH, was added 12.0 ml (100 mmol) of 1-amino-4-methylpiperazine, 2.8 g (50 mmol) of KOH. The mixture was heated to 80°C for 2 hours, concentrated in vacuo, diluted with 250 ml of Et₂O, and washed with 100 ml of H₂O. The resultant layers were separated and the organic layer was dried over Na₂SO₄, filtered and concentrated in vacuo to provide a thick oil. This oil was purified using radial chromatography (4000 micron plate, gradient eluent of 0-15% MeOH in EtOAc).


Yield: 2.29 g (88%).

¹H NMR (300MHz, CDCl₃): δ 8.13 (d, J=8Hz, 1H); 6.80 (d, J=4Hz, 1H); 6.72 (dd, J=4,8Hz, 1H); 3.80 (s, 3H); 3.70 (s,

- 59 -

3H); 3.66 (m, 1H); 2.95 (m, 2H); 2.80 (m, 2H); 2.70 (m, 1H);
2.60 (m, 4H); 2.35 (s, 3H); 2.26 (m, 2H); 1.95 (m, 1H); 1.70
(m, 2H); 1.45 (m, 1H); 1.30 (s, 3H); 1.10 (m, 1H) and 1.03
(s, 3H).

5

Example 42

10

The compound was prepared substantially in accordance
with the procedure detailed in Example 40, using 2.29 g (5.54
mmol) of the compound of Example 41, and 5.54 ml of a
solution consisting of 1.0 ml concentrated HCl and 11.0 ml of
CH₃CN.

Yield: 2.31 g (93%).

15

¹H NMR (300MHz, d₆-DMSO): δ 10.5 (bs, 1H); 8.02 (d, J=8Hz,
1H); 6.88 (d, J=4Hz, 1H); 6.80 (dd, J=4,8Hz, 1H); 3.78 (s,
3H); 3.64 (s, 3H); 3.50 (m, 1H); 3.33 (m, 4H); 3.03 (m, 4H);
2.63 (m, 1H); 2.77 (s, 3H); 2.30 (m, 1H); 2.10 (m, 1H); 1.84
(m, 1H); 1.68 (m, 1H); 1.58 (m, 1H); 1.31 (m, 1H); 1.20 (s,
3H); 1.10 (m, 1H) and 0.93 (s, 3H).

20


MS: m/e 413 (M⁺-HCl).

Elemental Analysis for C₂₄H₃₆N₃O₃Cl:

Calcd: C, 64.05; H, 8.06; N, 9.34; Cl, 7.21;

Found: C, 63.85; H, 7.98; N, 9.50; Cl, 7.67.

25

Example 43

- 60 -


To a solution of 330 mg (1.04 mmol) of the compound from Example 6 in 4.0 ml of EtOH was added 100 mg (1.2 mmol) of methoxyamine hydrochloride and 98 mg (1.2 mmol) of NaOAc. The reaction mixture was stirred at room temperature for 67 hours, heated to 80°C and reacted for approximately 3 hours and then concentrated in vacuo. The crude material was purified using radial chromatography (2000 micron plate, eluent of 3% EtOAc in CH₂Cl₂) to provide an oil which was dissolved in MeOH and recrystallized at 0°C.

Yield: 43 mg (12%).

¹H NMR (300MHz, CDCl₃): δ 7.95 (d, J=8Hz, 1H); 6.83 (d, J=4Hz, 1H); 6.75 (dd, J=4,8Hz, 1H); 4.0 (s, 3H); 3.82 (s, 3H); 3.72 (s, 3H); 3.32 (m, 1H); 2.97 (m, 1H); 2.28 (m, 2H); 1.98 (m, 1H); 1.68 (m, 2H); 1.52 (m, 1H); 1.25 (s, 3H); 1.10 (m, 1H) and 0.98 (s, 3H).

MS: m/e 345 (M+).

Example 44




To a solution of 175 mg (0.528 mmol) of the compound from Example 7 in 3.0 ml of dioxane, was added 235 mg (1.70 mmol) of K₂CO₃ and 112 mg (0.687 mmol) of 3-picolyl chloride hydrochloride. The reaction mixture was heated to 100°C, reacted for 15 minutes and then concentrated in vacuo to provide a tan residue. This residue was dissolved in 75.0 ml of EtOAc, washed with a saturated NaHCO₃ solution, dried over Na₂SO₄, filtered and then concentrated in vacuo to provide 180 mg of crude material which was purified using radial chromatography (2000 micron plate, gradient eluent of 5-20% EtOAc in CH₂Cl₂).

Yield: 90 mg (40%).

- 61 -

¹H NMR (300MHz, CDCl₃): δ 8.70 (m, 1H); 8.55 (m, 1H); 7.9 (d, J=8Hz, 1H); 7.77 (m, 1H); 7.30 (m, 1H); 6.80 (d, J=4Hz, 1H); 6.72 (dd, J=4,8Hz, 1H); 5.22 (s, 2H); 3.80 (s, 3H); 3.70 (s, 3H); 3.37 (m, 1H); 3.02 (m, 1H); 2.25 (m, 2H); 1.95 (m, 1H); 1.67 (m, 2H); 1.50 (m, 1H); 1.27 (s, 3H); 1.10 (m, 1H) and 0.97 (s, 3H).

Example 45


To a solution of 500 mg (1.58 mmol) of the compound from Example 6 in 5.0 ml of MeOH was added 101 mg (1.6 mmol) of sodium cyanoborohydride and a trace (a trace) of methyl orange. A 2N HCl methanolic solution was added dropwise to maintain the red color of the reaction. After approximately 15 minutes, the color stabilized (red) and the reaction was stirred for 45 minutes longer. The reaction mixture was concentrated in vacuo to provide an orange residue. The residue was dissolved in Et₂O and washed with brine, dried over Na₂SO₄, filtered and concentrated in vacuo to provide an oil which solidified on standing. The solid was purified using radial chromatography (4000 micron plate, eluent of 5% EtOAc in CH₂Cl₂).

Yield: 226 mg (45%).

¹H NMR (300MHz, CDCl₃): δ 7.50 (d, J=8Hz, 1H); 6.77 (m, 2H); 4.68 (m, 1H); 3.80 (s, 3H); 3.62 (s, 3H); 2.55 (m, 1H); 2.22 (m, 2H); 1.90 (m, 3H); 1.58 (m, 2H); 1.35 (m, 1H); 1.27 (s, 3H); 1.03 (m, 1H) and 1.0 (s, 3H).

MS: m/e 318 (M⁺).


- 62 -

Example 46

To a solution of 1.0 g (3.16 mmol) of the compound from
Example 6 in 15.0 ml of MeOH, was added 1.0 g crushed and
activated 4.0Å molecular sieves, 2.46 g (32 mmol) of ammonium
acetate and 201 mg (3.2 mmol) of sodium cyanoborohydride.
The reaction was stirred at room temperature for 1 hour and
then quenched with 30.0 ml of H₂O. The desired compounds
were extracted with 100 ml of Et₂O, washed with a saturated
NaHCO₃ solution, dried over Na₂SO₄, filtered and then
concentrated in vacuo to provide a yellow residue. This
residue was purified using flash chromatography (SiO₂,
gradient eluent of 0-5% EtOAc in CH₂Cl₂).

Yield: 290 mg (29%).

¹H NMR (300MHz, CDCl₃): δ 7.45 (d, J=8Hz, 1H); 6.78 (m, 2H);
3.85 (m, 1H); 3.78 (s, 3H); 3.67 (s, 3H); 2.40 (m, 1H); 2.22
(m, 2H); 1.95 (m, 2H); 1.78 (m, 1H); 1.58 (m, 3H); 1.40 (m,
1H); 1.27 (s, 3H); 1.10 (m, 1H) and 1.05 (s, 3H).

Example 47

To a solution of 20 mg (0.063 mmol) of the compound from
Example 46 in 3.0 ml of a 2:1 Et₂O/hexane mixture, was added
63 µl of a solution consisting of 1.0 ml of concentrated HCl
in 11.0 ml of CH₃CN. The resultant precipitate was filtered,

- 63 -


washed with 3.0 ml of a 1:1 Et₂O/hexane mixture and dried in vacuo.

Yield: 21 mg (95%).

¹H NMR (300MHz, d₆-DMSO): δ 8.42 (m, 3H); 7.50 (d, J=8Hz, 1H); 6.82 (m, 2H); 4.35 (m, 1H); 3.70 (s, 3H); 3.58 (s, 3H); 2.50 (m, 1H); 2.20 (m, 2H); 1.87 (m, 2H); 1.58 (m, 2H); 1.25 (m, 1H); 1.20 (s, 3H); 1.10 (m, 1H) and 1.0 (s, 3H).

MS: m/e 317 (M+).

Example 48




To a solution of 1.0 g (3.16 mmol) of the compound from Example 6 in 15.0 ml of CH₂Cl₂, was added 0.44 ml (3.8 mmol) of 2,6-lutidine and 0.80 ml (3.5 mmol) of t-butyldimethylsilyl trifluoromethanesulfonate. The reaction mixture was stirred at room temperature for 1 hour, diluted with Et₂O and washed sequentially with H₂O and a saturated NaHCO₃ solution, dried over Na₂SO₄, filtered and concentrated in vacuo.

Yield: 1.36 g (quantitative).

¹H NMR (300MHz, CDCl₃): δ 7.42 (d, J=8Hz, 1H); 6.78 (d, J=4Hz, 1H); 6.72 (dd, J=4,8Hz, 1H); 5.55 (d, J=4Hz, 1H); 3.80 (s, 3H); 3.68 (s, 3H); 2.42 (d, J=4Hz, 1H); 2.30 (m, 1H); 2.15 (m, 1H); 1.95 (m, 1H); 1.65 (m, 2H); 1.27 (s, 3H); 1.10 (m, 1H); 1.03 (s, 9H); 0.90 (s, 3H); 0.28 (s, 3H) and 0.18 (s, 3H).


- 64 -

Example 49

To a solution of 1.36 g (3.16 mmol) of the compound from
Example 48 in 10.0 ml of THF, was added 1.6 ml of a 1M
bromine in AcOH solution. The reaction mixture was diluted
with Et₂O, washed with a saturated NaHCO₃ solution, dried over
Na₂SO₄, filtered and then concentrated in vacuo to provide a
yellow solid. This solid was dissolved in 10.0 ml of MeOH,
cooled to 0°C and reacted for 18 hours. The resultant white
crystals were filtered and dried in vacuo.

Yield: 935 mg (75%).

¹H NMR (300MHz, CDCl₃): δ 7.82 (d, J=8Hz, 1H); 6.88 (dd,
J=4,8Hz, 1H); 6.83 (d, J=8Hz, 1H); 5.82 (d, J=6Hz, 1H); 3.86
(s, 3H); 3.73 (s, 3H); 2.52 (d, J=6Hz, 1H); 2.37 (m, 1H);
2.17 (m, 1H); 1.92 (m, 1H); 1.78 (m, 2H); 1.57 (s, 3H); 1.22
(m, 1H) and 0.87 (s, 3H).

Example 50

To a solution of 910 mg (2.30 mmol) of the compound from
Example 49 in 10.0 ml of MeOH, was added 11.2 ml (5.6 mmol)
of a 0.5M sodium methoxide (NaOMe) in MeOH solution. The
reaction mixture was heated to 65°C for 5 hours and then
concentrated in vacuo to provide a residue which was
dissolved in a 2:1 Et₂O/H₂O mixture. The resulting layers

- 65 -

were separated and the organic layer was dried over Na_2SO_4 , filtered and concentrated in vacuo.

Yield: 705 mg (98%).

^1H NMR (300MHz, CDCl_3): δ 8.15 (d, $J=8\text{Hz}$, 1H); 6.93 (m, 2H); 6.57 (s, 1H); 3.87 (s, 3H); 3.63 (s, 3H); 2.52 (m, 1H); 2.30 (m, 1H); 2.13 (m, 1H); 1.70 (m, 1H); 1.50 (m, 1H); 1.47 (s, 3H); 1.31 (s, 3H) and 1.24 (m, 1H).


MS: m/e 314 (M^+).

Elemental Analysis for $\text{C}_{19}\text{H}_{22}\text{O}_4$:

Calc: C, 72.59; H, 7.05;

Found: C, 72.72; H, 7.13.

Example 51



To a solution of 100 mg (0.318 mmol) of the compound from Example 50 in 5.0 ml of EtOH, was added 1.47 g (21.2 mmol) of hydroxylamine hydrochloride and 1.74 g (21.2 mmol) of NaOAc. The reaction mixture was heated to 78°C and reacted for 18 hours and then concentrated in vacuo to provide a residue which was dissolved in a 2:1 EtOAc/ H_2O mixture. The resultant layers were separated and the organic layer was dried over Na_2SO_4 , filtered and concentrated in vacuo to provide a yellow solid which was purified using radial chromatography (1000 micron plate (eluent of 1% MeOH in CH_2Cl_2)).

Yield: 87 mg (83%).

^1H NMR (300MHz, CDCl_3): δ 8.30 (bs, 1H); 7.95 (d, $J=8\text{Hz}$, 1H); 7.30 (s, 1H); 6.85 (m, 2H); 3.82 (s, 3H); 3.62 (s, 3H); 2.45 (m, 1H); 2.25 (m, 1H); 2.10 (m, 1H); 1.65 (m, 1H); 1.57 (m, 1H); 1.53 (s, 3H); 1.27 (s, 3H) and 1.22 (m, 1H).

MS: m/e 329 (M^+).


- 66 -

Elemental Analysis for $C_{19}H_{23}NO_4$:

Calc: C, 69.28; H, 7.04; N, 4.25;

Found: C, 69.29; H, 7.23; N, 4.23.


5

Example 52

To a solution of 150 mg (0.48 mmol) of the compound from Example 50 in 2.0 ml of EtOH, was added 28 μ l (0.48 mmol) of AcOH and 555 μ l (11.4 mmol) of hydrazine. The reaction mixture was heated to 80°C for 7 hours, concentrated in vacuo to provide a residue. This residue was diluted with 100 ml of Et₂O, washed with a saturated NaHCO₃ solution, dried over Na₂SO₄, filtered and concentrated in vacuo to provide an oily residue. This residue was dissolved in 5.0 ml of hot hexane and cooled to 0°C for 16 hours.

Yield: 135 mg (85%).

¹H NMR (300MHz, CDCl₃): δ 8.0 (d, J=8Hz, 1H); 6.80 (m, 3H); 5.40 (s, 2H); 3.80 (s, 3H); 3.60 (s, 3H); 2.45 (m, 1H); 2.27 (m, 1H); 2.08 (m, 1H); 1.70 (m, 1H); 1.55 (m, 1H); 1.27 (s, 3H) and 1.22 (m, 1H).


MS: m/e 328 (M⁺).Example 53

To a cold (0°C) solution of 595 mg (1.87 mmol) of the compound from Example 45 in 3.5 ml of CH₃CN, was added a mixture containing 2.0 ml CF₃COOH/0.1 ml CH₃CN/0.2 ml H₂O. The reaction mixture was warmed to room temperature, stirred for 30 minutes and then diluted with 50.0 ml of EtOAc. The resultant layers were separated and the organic layer was washed sequentially with H₂O and a saturated NaHCO₃ solution, dried over Na₂SO₄, filtered and concentrated in vacuo.

Yield: 494 mg (88%).

¹H NMR (300MHz, CDCl₃): δ 7.0 (d, J=8Hz, 1H); 6.80 (d, J=4Hz, 1H); 6.67 (dd, J=4,8Hz, 1H); 6.40 (m, 2H); 3.80 (s, 3H); 3.70 (s, 3H); 2.35 (m, 2H); 2.20 (m, 1H); 1.95 (m, 1H); 1.65 (m, 2H); 1.30 (s, 3H); 1.13 (m, 1H) and 0.87 (s, 3H).

Example 54



To a solution of 1.0 g (3.31 mmol) of the compound from Example 1A in 10.0 ml of THF, was added 1.0 g (6.4 mmol) of benzeneselenol, 302 mg (6.29 mmol) of a 50% dispersion of NaH in mineral oil and 84 mg (0.32 mmol) of 18-crown-6 ether. The reaction mixture was refluxed for 15 hours, cooled to room temperature and diluted with 100 ml of Et₂O and 20 ml of 1N HCl. The resultant layers were separated and the organic layer was dried over Na₂SO₄, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (SiO₂, eluent of 25% EtOAc in hexane) to provide a solid which was recrystallized from Et₂O/hexane.

Yield: 731 mg (77%).

¹H NMR (300MHz, CD₃OD): δ 6.9 (d, J=8Hz, 1H); 6.75 (d, J=4Hz, 1H); 6.60 (dd, J=4,8Hz, 1H); 3.70 (s, 3H); 2.70 (m, 2H); 2.20


- 68 -

(m, 3H); 2.20 (m, 2H); 1.53 (m, 2H); 1.33 (m, 1H); 1.27 (s, 3H); 1.10 (s, 3H) and 1.07 (m, 1H).

MS: m/e 288 (M+).

5

Example 55




To a solution of 360 mg (1.25 mmol) of the compound from Example 54 in 25.0 ml of toluene, was added 0.545 ml (6.25 mmol) of oxalyl chloride in 25 μ l of DMF. The reaction mixture was stirred at room temperature with gas evolution for 30 minutes, heated briefly (2 minutes) to reflux and then concentrated in vacuo.

Yield: 381 mg crystals (99%).

^1H NMR (300MHz, CDCl_3): δ 6.98 (d, $J=8\text{Hz}$, 1H); 6.82 (d, $J=4\text{Hz}$, 1H); 6.68 (dd, $J=4,8\text{Hz}$, 1H); 3.80 (s, 3H); 2.80 (m, 2H); 2.25 (m, 3H); 2.05 (m, 2H); 1.65 (m, 2H); 1.42 (m, 1H); 1.40 (s, 3H); 1.25 (s, 3H) and 1.20 (m, 1H).

20

Example 56



To a solution of 100 mg (0.33 mmol) of the compound from Example 55 in 2.0 ml of CH_2Cl_2 , were added 43 μ l (0.358 mmol) of 2-(2-aminoethyl)pyridine, 50 μ l (0.36 mmol) of Et_3N and 5 mg (0.036 mmol) of 4-dimethylaminopyridine in 4.0 ml of

- 69 -


CH₂Cl₂. The reaction mixture was diluted with CH₂Cl₂, washed with H₂O, dried over Na₂SO₄, filtered and concentrated in vacuo to provide a tan solid. This solid was dissolved in 3.0 ml of CH₃CN and treated with 0.36 ml of a solution of 1.0 ml of concentrated HCl in 11.0 ml of CH₃CN.

Yield: 120 mg (78%).

¹H NMR (300MHz, d₆-DMSO): δ 8.75 (d, J=6Hz, 1H); 8.40 (t, J=6Hz, 1H); 7.80 (m, 2H); 7.40 (m, 1H); 6.85 (d, J=8Hz, 1H); 6.70 (d, J=4Hz, 1H); 6.60 (dd, J=4, 8Hz, 1H); 3.60 (s, 3H); 3.55 (m, 2H); 3.19 (m, 2H); 2.68 (m, 1H); 2.55 (m, 1H); 2.10 (m, 3H); 1.78 (m, 2H); 1.43 (m, 1H); 1.30 (m, 1H); 1.17 (m, 1H); 1.02 (s, 3H); 0.99 (m, 1H) and 0.80 (s, 3H).

MS: m/e 392 (M⁺-HCl).

Example 57



To a solution of NaOMe (prepared in situ from 2.6 g of sodium and 400 ml of anhydrous MeOH (0.108 mol), under N₂), was added 15.0 g (0.035 mol) of 70% abietic acid. After stirring the mixture for 10 minutes, 14.0 ml (0.22 mol) of iodomethane was added and the mixture was refluxed for 24 hours, cooled and concentrated in vacuo to provide a residue. This residue was dissolved in 500 ml of EtOAc, washed sequentially with 500 ml of a saturated NaHCO₃ solution and a saturated sodium chloride solution (NaCl), dried over Na₂SO₄, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (eluent of 2% EtOAc in hexanes).

Yield: 10.0 g of a dark yellow oil (90.4%).

IR(CHCl₃): 2952, 1718 and 1251 cm⁻¹.

- 70 -

¹H NMR (300MHz, CDCl₃): δ 5.78 (s, 1H); 5.38 (brs, 1H); 3.66 (s, 3H); 2.17-2.30 (m, 3H); 1.68-2.16 (m, 8H); 1.50-1.65 (m, 2H); 1.26 (s, 3H); 1.24 (m, 2H); 1.02 (d, J=2.6Hz, 3H); 1.00 (d, J=2.6Hz, 3H) and 0.83 (s, 3H).

5 MS(FD): m/e 316(M⁺).


Elemental Analysis for C₂₁H₃₂O₂:

Calcd: C, 79.70; H, 10.19;

Found: C, 79.49; H, 9.94.

10

Example 58



To a mixture of 5.0 g (15.8 mmol) of the compound in Example 57 in 100 ml of acetic anhydride, was added 2.5 g (22.5 mmol) of selenium (IV) oxide, under N₂. The reaction mixture was warmed to 70°C, stirred for 16 hours, cooled, filtered and then diluted to 500 ml with CH₂Cl₂. The resulting layers were separated and the organic layer was washed with 500 ml of NaCl, dried over Na₂SO₄, filtered and then concentrated in vacuo to provide a dark yellow solid. This solid was purified using flash chromatography (eluent of 5% EtOAc in hexanes) to provide two major fractions.

The first fraction was concentrated to provide 537 mg of an oil. This oil was hydrogenated with 135 mg of 5% Pd/C in 25 ml of MeOH (8 hours, room temperature, 6.0 psi). The reaction mixture was filtered and the filtrate concentrated in vacuo. The crude material was purified using flash chromatography (eluent of 2% EtOAc in hexanes) to provide the compound of Example 59 (400 mg of a clear oil (75%) m.p. 50°C). The second fraction was concentrated in vacuo to provide the compound.

- 71 -

Yield: 2.8 g of a light yellow solid (47%).

m.p. 165-167°C.

IR (KBr): 2956, 1722 and 1251 cm^{-1} .

^1H NMR (300MHz, CDCl_3): δ 7.23 (m, 2H); 7.04 (d, $J=1.8\text{Hz}$, 1H); 5.90 (m, 1H); 3.64 (s, 3H); 2.86 (m, 1H); 2.60 (dd, $J=1.5, 11.0\text{Hz}$, 1H); 2.31 (d, $J=12.1\text{Hz}$, 1H); 2.08 (s, 3H); 2.07 (m, 1H); 1.60-1.80 (m, 6H); 1.26 (s, 3H); 1.24 (s, 3H); 1.22 (s, 3H) and 1.19 (s, 3H).


MS(FD): m/e 372 (M^+).

Elemental Analysis for $\text{C}_{23}\text{H}_{32}\text{O}_4$:

Calcd: C, 74.16; H, 8.66;

Found: C, 74.44; H, 8.71.

Example 59



To a mixture of 23.6 g (0.063 mmol) of the compound in Example 58 in 1500 ml of MeOH, was added 5.8 g of 10% Pd/C and 5.8 g (0.030 mmol) of p-toluenesulfonic acid monohydrate. The reaction mixture was reacted for 16 hours at room temperature, 60 psi, filtered and then concentrated in vacuo to provide a residue. This residue was dissolved in 700 ml of EtOAc, washed sequentially with 700 ml of saturated NaHCO_3 and NaCl solutions, dried over Na_2SO_4 , filtered and then concentrated in vacuo.

Yield: 19.3 g (97.5%) of an oil.

IR (CHCl_3): 2955, 1718 and 1254 cm^{-1} .

^1H NMR (300MHz, CDCl_3): δ 7.16 (d, $J=8\text{Hz}$, 1H); 7.00 (d, $J=8\text{Hz}$, 1H); 6.88 (s, 1H); 3.66 (s, 3H); 2.80-2.90 (m, 3H); 2.23-2.32 (m, 2H); 1.35-1.90 (m, 7H); 1.28 (s, 3H); 1.24 (s, 3H) and 1.21 (s, 6H).

- 72 -


MS(FD): m/e 314(M+).

Elemental Analysis for C₂₁H₃₀O₂:

Calcd: C, 80.21; H, 9.62

Found: C, 80.34; H, 9.73

5


Example 60

To a suspension of 185 mg (0.50 mmol) of the compound of
10 Example 58 in 10 ml of MeOH, was added 5 ml (0.50 mmol) of
0.1N NaOH. The reaction mixture was refluxed for 2 hours,
cooled and partitioned between 50 ml of EtOAc and 50 ml of
0.2N HCl. The resulting layers were separated and the
organic layer was washed with 50 ml of a saturated NaCl
15 solution, dried over Na₂SO₄, filtered and then concentrated in
vacuo to provide a yellow oil which was purified using flash
chromatography (eluent of 10% EtOAc in hexanes).
Yield: 158 mg of a clear oil (96%).
m.p. 105-107°C.

20 IR (KBr): 2957, 3500 and 1719 cm⁻¹.
¹H NMR (300MHz, CDCl₃): δ 7.20 (m, 3H); 4.75 (t, J=4.8Hz,
1H); 3.69 (s, 3H); 2.88 (m, 1H); 2.50 (dd, J=1.8,13.2Hz, 1H);
2.30 (brd, J=12.1Hz, 1H); 2.06-2.17 (m, 1H); 1.98 (d,
J=7.0Hz, 1H); 1.69-1.84 (m, 4H); 1.55 (m, 2H); 1.29 (s, 3H);
25 1.25 (s, 3H); 1.23 (s, 3H) and 1.17 (s, 3H).

MS(FD): m/e 330(M+).

- 73 -

Example 61

To a solution of 112 mg (0.30 mmol) of the titled compound of Example 60 in 4 ml of glacial AcOH and 1 ml of H_2O , was added 10 mg (1.0 mmol) of chromium trioxide. The resultant mixture was stirred at room temperature for 1 hour and then partitioned between 50 ml of EtOAc and 50 ml of a saturated NaCl solution. The resultant layers were separated and the organic layer was dried over Na_2SO_4 , filtered and then concentrated in vacuo to provide a dark oil. This oil was purified using flash chromatography (eluent of 5% EtOAc in hexanes) to provide an oil which solidified on standing. Yield: 100 mg (90%).

IR (CHCl_3): 2965, 1722, 1675 and 1253 cm^{-1} .

^1H NMR (300MHz, CDCl_3): δ 7.88 (d, $J=1.8\text{Hz}$, 1H); 7.42 (dd, $J=1.8, 8.1\text{Hz}$, 1H); 7.30 (d, $J=8.1\text{Hz}$, 1H); 3.66 (s, 3H); 2.86-2.98 (m, 1H); 2.66-2.76 (m, 2H); 2.28-2.40 (m, 2H); 1.60-1.90 (m, 5H); 1.35 (s, 3H); 1.26 (s, 6H) and 1.24 (s, 3H).


MS(FD): m/e 329 (M^+).

Elemental Analysis for $\text{C}_{21}\text{H}_{28}\text{O}_3$:

Calcd: C, 76.79; H, 8.59;

Found: C, 76.52; H, 8.53.


- 74 -

Example 62

A mixture containing 118 mg (0.36 mmol) of the compound
of Example 61, 40 mg (0.58 mmol) of hydroxylamine
hydrochloride, 40 mg (0.48 mmol) of NaHCO₃, 1 drop of glacial
AcOH, 1.0 ml of H₂O and 15 ml of MeOH was with a Dean-Stark
trap for approximately 5 hours. The reaction mixture was
concentrated in vacuo to provide a residue. This residue was
partitioned between H₂O and CH₂Cl₂ and the organic layer was
dried over Na₂SO₄, filtered and concentrated in vacuo. The
crude material was purified using flash chromatography.
Yield: 120 mg (97%).

IR(CHCl₃): 3582, 2962, 1721 and 1261 cm⁻¹.

¹H NMR (300MHz, CDCl₃): δ 7.71 (s, 1H); 7.43 (s, 1H); 7.21
(s, 2H); 3.66 (s, 3H); 2.85-2.95 (m, 1H); 2.67 (m, 2H); 2.26-
2.37 (m, 2H); 1.75 (m, 5H); 1.38 (s, 3H); 1.26 (s, 3H); 1.24
(s, 3H); 1.13 (s, 3H); MS(FD) m/e 343(M⁺).

Example 63

A mixture of 500 mg (1.59 mmol) of the compound of
Example 59, 1.0 g (17.8 mmol) of KOH and 20 ml of n-butyl
alcohol was refluxed for 16 hours, under N₂. After cooling,
the mixture was acidified with 5N HCl and concentrated in

- 75 -

vacuo to provide a residue. This residue was suspended in 50 ml of H₂O and filtered. The resulting solid was dissolved in 50 ml of MeOH, filtered and the filtrate was concentrated in vacuo.

5 Yield: 330 mg of a foam (69%).

m.p. 143-145°C.

IR (KBr): 2958, 1695 and 1279 cm⁻¹.


10 ¹H NMR (300MHz, CDCl₃): δ 7.25 (d, J=3Hz, 1H); 7.17 (d, J=8Hz, 1H); 7.00 (dd, J=3.9Hz, 1H); 6.89 (brs, 1H); 2.80-3.00 (m, 3H); 2.20-2.40 (m, 2H); 1.65-1.96 (m, 5H); 1.43-1.60 (m, 2H); 1.29 (s, 3H); 1.24 (s, 3H); 1.22 (s, 3H); 1.21 (s, 3H); MS(FD) m/e 301(M⁺).

Elemental Analysis for C₂₀H₂₈O₂·0.5H₂O:

Calcd: C, 79.01; H, 9.47;

15 Found: C, 79.19; H, 9.52.

Example 64



20 To a cold (0°C) solution of 8.0 g (25.0 mmol) of the compound of Example 59 in 50 ml of acetic anhydride and 38 ml of AcOH, was added 11.0 g (0.11 mmol) of chromium trioxide slowly, under N₂. The reaction mixture was partitioned between EtOAc and brine and the organic layer was dried over

25 Na₂SO₄, filtered and concentrated to provide a yellow oil which was purified using flash chromatography (SiO₂, eluent of 10% EtOAc in hexanes) to provide a solid which was filtered with the aid of hexanes.

Yield: 2.5 g (30.5%).

30 m.p. 144-145°C.

IR (KBr): 2951, 1725 and 1680 cm⁻¹.

- 76 -

^1H NMR (300MHz, CDCl_3): δ 8.55 (d, $J=2\text{Hz}$, 1H); 8.17 (dd, $J=2,8\text{Hz}$, 1H); 7.50 (d, $J=8\text{Hz}$, 1H); 3.66 (s, 3H); 2.75 (m, 2H); 2.64 (s, 3H); 2.37-2.50 (m, 2H); 1.60-1.90 (m, 5H); 1.37 (s, 3H) and 1.29 (s, 3H).


MS(FD): m/e 328 (M^+).

Elemental Analysis for $\text{C}_{20}\text{H}_{24}\text{O}_4$:

Calcd: C, 73.15; H, 7.37;

Found: C, 72.86; H, 7.42.

Example 65



The compound was isolated from the reaction mixture described in Example 64.

Yield: 4.2 g of a white solid (43.5%).

m.p. 130-133°C.

IR (KBr): 2934, 1734, 1720 and 1680 cm^{-1} .

^1H NMR (300MHz, CDCl_3): δ 7.98 (d, $J=2\text{Hz}$, 1H); 7.54 (dd, $J=2,8\text{Hz}$, 1H); 7.33 (d, $J=8\text{Hz}$, 1H); 3.66 (s, 3H); 2.75 (m, 2H); 2.30-2.42 (m, 2H); 2.2 (m, 1H); 2.04 (s, 3H); 2.00-2.10 (m, 1H); 1.70-1.90 (m, 3H); 1.76 (s, 6H); 1.35 (s, 3H) and 1.26 (s, 3H).


MS(FD): m/e 386 (M^+).

Elemental Analysis for $\text{C}_{23}\text{H}_{30}\text{O}_5$:

Calcd: C, 71.48; H, 7.82;

Found: C, 71.75; H, 8.03.

- 77 -

Example 66

To a solution of 4.14 g (10.7 mmol) of the compound of Example 65 in 40 ml of MeOH, was added 13.4 ml (13.4 mmol) of 1N NaOH. The reaction mixture was refluxed for 2.5 hours, cooled and then partitioned between 200 ml of 0.2N HCl and 200 ml of EtOAc. The resultant layers were separated and the organic layer was washed with 200 ml of brine, dried over Na₂SO₄, filtered and then concentrated in vacuo to provide a dark yellow oil. This oil was purified using flash chromatography (SiO₂, eluent of 15% EtOAc in hexanes). Yield: 2.9 g of a white foam (80%).

m.p. 57-60°C.

IR(KBr): 3444, 2936, 1727 and 1682 cm⁻¹.

¹H NMR (300MHz, CDCl₃): δ 8.06 (d, J=2.2Hz, 1H); 7.74 (dd, J=2.2,8.5Hz, 1H); 7.36 (d, J=8.5Hz, 1H); 3.66 (s, 3H); 2.70 (m, 2H); 2.40 (m, 2H); 1.60-1.90 (m, 6H); 1.60 (s, 3H); 1.55 (s, 3H); 1.35 (s, 3H) and 1.27 (s, 3H).


MS(FD): m/e 344(M⁺).

Elemental Analysis for C₂₁H₂₈O₄:

Calcd: C, 73.23; H, 8.19;

Found: C, 73.50; H, 8.46.

- 78 -

Example 67

A mixture of 500 mg (1.52 mmol) of the compound of Example 64, 620 mg (1.80 mmol) of 50% m-chloroperbenzoic acid, 5.0 mg (0.03 mmol) of p-toluene sulfonic acid monohydrate and 5 ml of 1,2-dichloroethane was refluxed for 4 hours and then stirred overnight at room temperature. The mixture was diluted with 25 ml of EtOAc and washed sequentially with 25 ml of 10% potassium iodide, 10% sodium thiosulfate, saturated NaHCO₃ and brine, dried over Na₂SO₄, filtered and then concentrated in vacuo. The crude material was purified by radial chromatography (eluent of 25% Et₂O in hexanes).

Yield: 30 mg (6%).

IR(CHCl₃): 3020, 1723 and 1684 cm⁻¹.

¹H NMR (300MHz, CDCl₃): δ 7.69 (d, J=3Hz, 1H); 7.39 (d, J=9Hz, 1H); 7.24 (d, J=3Hz, 1H); 3.67 (s, 3H); 2.84 (m, 2H); 2.25-2.42 (m, 2H); 2.31 (s, 3H); 1.60-1.90 (m, 5H); 1.35 (s, 3H) and 1.28 (s, 3H).


MS(FD): m/e 344(M⁺).

Elemental Analysis for C₂₀H₂₄O₅:

Calcd: C, 69.75; H, 7.02;

Found: C, 69.77; H, 6.92.

- 79 -

Example 68

The compound was prepared substantially in accordance with the procedure detailed in Matsumoto et al., Bull. Chem. Soc. Jpn., vol. 61, pages 723-727 (1988), using the compound of Example 64.

Yield: 42%.

IR(CHCl₃): 3389, 2948, 1725, 1670, 1606 cm⁻¹.


¹H NMR (300MHz, CDCl₃): δ 7.45 (d, J=3Hz, 1H); 7.27 (d, J=9Hz, 1H); 7.07 (dd, J=3,9Hz, 1H); 5.20 (s, 1H); 3.66 (s, 3H); 2.65-2.80 (m, 2H); 2.27-2.42 (m, 2H); 1.60-1.90 (m, 5H); 1.34 (s, 3H) and 1.25 (s, 3H).

MS(FD): m/e 302 (M⁺).

Elemental Analysis for C₁₈H₂₂O₄:

Calcd: C, 71.50; H, 7.33;

Found: C, 71.22; H, 7.19.

Example 69

The compound was prepared substantially in accordance with the procedure detailed in Matsumoto et al., Bull. Chem. Soc. Jpn., vol. 61, 723-727 (1988), using the compound of Example 68.

Yield: 86%.

- 80 -

IR(CHCl₃): 2941, 1722, 1677 and 1252 cm⁻¹.

¹H NMR (300MHz, CDCl₃): δ 7.48 (d, J=3Hz, 1H); 7.29 (d, J=9Hz, 1H); 7.11 (dd, J=3,9Hz, 1H); 3.84 (s, 3H); 3.66 (s, 3H); 2.70 (m, 2H); 2.30-2.43 (m, 2H); 1.60-1.90 (m, 5H); 1.34 (s, 3H) and 1.25 (s, 3H).


MS(FD): m/e 316(M⁺).

Elemental Analysis for C₁₉H₂₄O₄:

Calcd: C, 72.13; H, 7.65;

Found: C, 72.16; H, 7.35.

Example 70




A mixture of 475 mg (1.5 mmol) of the compound of Example 60B, 425 mg (3.19 mmol) of anhydrous aluminum chloride in 15 ml of toluene was stirred at room temperature for 2 hours, under N₂. The reaction mixture was partitioned between toluene and 1N HCl. The resultant layers were separated and the organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated in vacuo to provide an oil. This oil was purified using flash chromatography (SiO₂, eluent of 2% EtOAc in hexanes) to provide an oil which was crystallized from MeOH.

¹H NMR (300MHz, CDCl₃): δ 7.00-7.30 (m, 4H); 3.30 (s, 1.5H); 3.28 (s, 1.5H); 2.90 (m, 2H); 2.30 (m, 2H); 2.00 (m, 1H); 1.40-1.80 (m, 6H); 1.30 (s, 1.5H); 1.22 (s, 3H) and 1.10 (s, 1.5H).

- 81 -

B.



A solution of 285 mg (2.8 mmol) of chromium trioxide in 4 ml of glacial AcOH and 1 ml of H₂O was added dropwise to a solution of 275 mg (1 mmol) of the compound of Example 70A in 5 ml of glacial AcOH. The reaction mixture was stirred at room temperature for 2 hours and then partitioned between EtOAc and brine (twice). The combined organic layers were dried over Na₂SO₄, filtered and then concentrated in vacuo to provide a yellow oil. This oil was purified using flash chromatography (SiO₂, eluent of 5% EtOAc in hexanes) to provide a bright yellow solid.

Yield: 50 mg (17%).

m.p. 121-123°C.

IR(CHCl₃): 3019, 2954, 1727, 1688 and 1248 cm⁻¹.

¹H NMR (300MHz, CDCl₃): δ 8.14 (d, J=8Hz, 1H); 7.70 (7, J=7Hz, 1H); 7.47 (m, 2H); 3.73 (s, 3H); 3.39 (s, 1H); 2.64 (d, J=12Hz, 1H); 2.01-2.11 (m, 1H); 1.40-1.80 (m, 4H); 1.29 (s, 3H) and 0.69 (s, 3H).


MS(FD): m/e 300(M⁺).

Elemental Analysis for C₁₈H₂₀O₄:

Calcd: C, 71.98; H, 6.71;

Found: C, 72.10; H, 6.66.

C.



The compound was isolated from the reaction mixture described in Example 70B.


- 82 -

Yield: 136 mg of an oil (47.5%).

^1H NMR (300MHz, CDCl_3): δ 8.01 (m, 1H); 7.55 (m, 1H); 7.30 (m, 2H); 3.30 (s, 1.5H); 3.28 (s, 1.5H); 3.10 (dd, $J=4,12\text{Hz}$, 0.5H); 2.70 (m, 1.5H); 2.40 (m, 2H); 1.40-1.90 (m, 5H); 1.30 (s, 1.5H); 1.28 (s, 1.5H); 1.23 (s, 1.5H); 0.65 (s, 1.5H).

Example 71

A.




A solution of 0.9 ml (17 mmol) of bromine in 30 ml of anhydrous Et_2O was added to a solution of 3.8 g (13.3 mmol) of the compound of Example 70C in 200 ml of anhydrous Et_2O , dropwise. The reaction mixture was stirred at room temperature for 1 hour and then washed sequentially with H_2O , a saturated NaHCO_3 solution and 19% sodium thiosulfate, dried over Na_2SO_4 , filtered and concentrated in vacuo to provide a residue which was purified using flash chromatography (eluent of 3:2 CH_2Cl_2 /hexanes).

Yield: 1.2 g of yellowish oil (25%).

^1H NMR (300MHz, CDCl_3): δ 8.00 (dd, $J=2,5\text{Hz}$, 1H); 7.60 (dt, $J=2,5\text{Hz}$, 1H); 7.40 (m, 2H); 4.60 (s, 1H); 3.78 (s, 3H); 3.25 (s, 1H); 2.50 (d, $J=7\text{Hz}$, 1H); 1.60-1.90 (m, 5H); 1.60 (s, 3H); 0.57 (s, 3H).

B.




The compound was isolated from the reaction mixture described in Example 71A.

- 83 -

Yield: 1.2 g of an oil (25%).

^1H NMR (300MHz, CDCl_3): δ 8.01 (d, $J=6\text{Hz}$, 1H); 7.60 (m, 1H); 7.40 (m, 2H); 5.00 (d, $J=9\text{Hz}$, 1H); 3.65 (s, 3H); 3.23 (d, $J=9\text{Hz}$, 1H); 2.60 (m, 1H); 2.38 (d, $J=7\text{Hz}$, 1H); 1.80 (m, 4H); 1.52 (s, 3H) and 1.25 (s, 3H).

Example 72



A mixture of 1.2 g (3.3 mmol) of the compound of Example 71A, 450 mg (6.9 mmol) of zinc dust, 225 mg (2.7 mmol) of NaOAc and 50 ml of glacial AcOH was refluxed for 1 hour, under N_2 . After cooling, the reaction mixture was filtered and the filtrate was partitioned between Et_2O and brine. The resultant layers were separated and the organic layer was dried over Na_2SO_4 , filtered and then concentrated in vacuo. The crude material was purified using flash chromatography (SiO_2 , eluent of 10% Et_2O in hexanes).

Yield: 897 mg of a pale yellow oil (93%).

IR(CHCl_3): 3018, 1721, 1675 and 1257 cm^{-1} .

^1H NMR (300MHz, CDCl_3): δ 8.03 (m, 1H); 7.55 (m, 1H); 7.30 (m, 2H); 3.69 (s, 3H); 3.13 (dd, $J=7, 19\text{Hz}$, 1H); 2.76 (dd, $J=3, 7\text{Hz}$, 1H); 2.50 (d, $J=3\text{Hz}$, 1H); 2.45 (t, $J=3\text{Hz}$, 1H); 1.88 (m, 1H); 1.58 (m, 4H); 1.33 (s, 3H) and 0.69 (s, 3H).

MS(FD): m/e 286(M^+).

Elemental Analysis for $\text{C}_{18}\text{H}_{22}\text{O}_3$:


Calcd: C, 75.50; H, 7.74;

Found: C, 75.75; H, 7.89.

- 84 -

Example 73

A.



The compound was prepared substantially in accordance with the procedure detailed in Example 72, using 960 mg (2.6 mmol) of the compound of Example 71B, 4.0 g (61.2 mmol) of zinc dust, 2.0 g (24.4 mmol) of NaOAc and 50 ml of glacial AcOH. The crude material was purified using column chromatography.


Yield: 500 mg of an oil (67.2%).

IR(CHCl₃): 3028, 1722, 1679, 1258 cm⁻¹.

¹H NMR (300MHz, CDCl₃): δ 8.01 (d, J=8Hz, 1H); 7.54 (7, 6Hz, 1H); 7.29 (m, 2H); 3.67 (s, 3H); 2.74 (dd, J=3,7Hz, 2H); 2.30-2.45 (m, 2H); 1.60-1.90 (m, 5H); 1.36 (s, 3H) and 1.28 (s, 3H).

MS(FD): m/e 286(M⁺).

B.




The compound was isolated from the reaction mixture described in Example 73A

Yield: 150 mg (21%).

- 85 -

Example 74

A.




A solution of 1.54 g (5.66 mmol) of the compound of
Example 70A and 1.5 g of 10% Pd/C in 150 ml of
triethyleneglycol dimethyl ether was refluxed for 3 hours,
under N₂. After cooling, the mixture was filtered and the
filtrate was partitioned between EtOAc and brine (three
times). The resultant layers were separated and the combined
organic layers were dried over Na₂SO₄, filtered and the
concentrated in vacuo to provide 1.5 g of a residue. A
fraction of this residue (300 mg) was purified by
chromatotron (eluent of 2% CH₂Cl₂ in hexanes initially,
followed by the addition to the mobile phase of 50 ml of
CH₂Cl₂ after 200 ml elution, and finally 4 ml of EtOAc after
300 ml had eluted).


Yield: 29 mg

¹H NMR (300MHz, CDCl₃): δ 7.00-7.30 (m, 4H); 3.63 (s, 3H);
2.83 (m, 2H); 2.90 (m, 3H); 2.00 (m, 2H); 1.30-1.70 (m, 3H);
1.25 (s, 3H); 1.10 (m, 1H); 1.02 (s, 3H).

B. A mixture of




and



The compounds were isolated from the reaction mixture
described in Example 74A.

Yield: 216 mg.

- 86 -



The compound was prepared substantially in accordance with the procedure detailed in Example 70B, using 70 mg (0.26 mmol) of the compound of Example 74A.

Yield: 30 mg of an off-white solid (40.3%).

m.p. 143-145°C.

IR(CHCl₃): 2951, 1718 and 1687 cm⁻¹.

¹H NMR (300MHz, CDCl₃): δ 8.05 (d, J=7Hz, 1H); 7.54 (m, 1H); 7.42 (d, J=7Hz, 1H); 7.31 (d, J=7Hz, 1H); 3.66 (s, 3H); 3.23 (dd, J=14,18Hz, 1H); 3.00 (dd, J=3,18Hz, 1H); 2.30-2.45 (m, 2H); 2.00-2.20 (m, 2H); 1.65-1.80 (m, 1H); 1.63 (m, 1H); 1.27 (s, 3H); 1.13 (s, 3H) and 1.12 (m, 1H).


MS(FD): m/e 286(M⁺).

Elemental Analysis for C₁₈H₂₂O₃:

Calcd: C, 75.50; H, 7.74;

Found: C, 75.78; H, 7.63.


Example 75



The compounds were prepared substantially in accordance with the procedure detailed in Example 70B, using a solution of 325 mg (1.2 mmol) of the unpurified residue from Example 74A in 5 ml of glacial AcOH. The crude material was purified using flash chromatography (SiO₂, eluent of 15% Et₂O in hexanes).

- 87 -

Yield: 62 mg of an oil.




The compound was isolated from the reaction mixture described in Example 75A.

Yield: 78 mg of an oil.

Note: The reaction mixture also provided 16 mg of the compound of Example 74C and 75 mg of the compound of Example 70A.

Example 76



The compound was prepared substantially in accordance with the procedure detailed in Example 62, using a solution containing 140 mg (0.49 mmol) of the compounds of Example 75A in 10 ml of MeOH. The crude material was purified using flash chromatography (SiO₂, eluent of 20% Et₂O in hexanes). Yield: 38 mg of a solid (26%).

m.p. 139-141°C.

IR(CHCl₃): 3584, 3020 and 1720 cm⁻¹.

¹H NMR (300MHz, CDCl₃): δ 7.92 (d, J=7.7Hz, 1H); 7.56 (s, 1H); 7.30 (m, 2H); 7.20 (m, 1H); 3.72 (s, 3H); 3.44 (dd, J=4.0, 18.4Hz, 1H); 3.12 (dd, J=14.0, 18.7Hz, 1H); 2.35 (m,

2H); 2.03 (m, 1H); 1.50-1.80 (m, 3H); 1.32 (s, 3H); 1.10 (m, 1H) and 1.02 (s, 3H).

- 88 -


MS(FD): m/e 301(M+).

Elemental Analysis for C₁₈H₂₃NO₃:

Calcd: C, 71.74; H, 7.69; N, 4.65;

Found: C, 71.97; H, 7.77; N, 4.39.

5



The compound was isolated from the reaction mixture described in Example 76A.


Yield: 38 mg of a resin (26%).

10 IR(CHCl₃): 3583, 3027, 2935, 1721 and 1263 cm⁻¹.

¹H NMR (300MHz, CDCl₃): δ 7.85 (d, J=8.1Hz, 1H); 7.43 (s, 1H); 7.10-7.20 (m, 3H); 3.66 (s, 3H); 2.67 (d, J=8.8Hz, 2H); 2.28-2.37 (m, 2H); 1.76 (m, 4H); 1.39 (s, 3H); 1.26 (m, 1H) and 1.14 (s, 3H).

15 MS(FD): m/e 301(M+).

Example 77



20 The compound was prepared substantially in accordance with the procedure detailed in Example 62, using the compound of Example 72.

Yield: 98%.

IR(CHCl₃): 3583, 2952 and 1720 cm⁻¹.

25 ¹H NMR (300MHz, CDCl₃): δ 7.86 (d, J=8.8Hz, 1H); 7.20-7.38 (m, 4H); 3.70 (s, 3H); 3.10 (dd, J=8.1, 19.8Hz, 1H); 2.53-2.64

- 89 -

(m, 2H); 2.47 (d, 11.4Hz, 1H); 1.70-1.90 (m, 1H); 1.40-1.60 (m, 4H); 1.19 (s, 3H) and 0.56 (s, 3H).


MS(FD): m/e 302(M+).

Elemental Analysis for $C_{18}H_{23}NO_3$:

Calcd: C, 71.73; H, 7.69; N, 4.65;

Found: C, 71.79; H, 7.78, N, 4.44.

Example 78



The compound was prepared substantially in accordance with the procedure detailed in Example 62, using the compound of Example 68.

IR(KBr): 3393, 2932, 1727 and 1702 cm^{-1} .

¹H NMR (300MHz, CDCl₃): δ 8.00 (brs, 1H); 7.29 (d, J=3Hz, 1H); 7.16 (d, J=9Hz, 1H); 6.85 (dd, J=3,9Hz, 1H); 5.25 (brs, 1H); 3.68 (s, 3H); 2.65 (m, 2H); 2.20-2.40 (m, 2H); 1.55-2.04 (m, 5H); 1.40 (s, 3H) and 1.10 (s, 3H).


MS(FD): m/e 318(M+).

Elemental Analysis for $C_{18}H_{23}O_4$:

Calcd: C, 68.12; H, 7.30; N, 4.41;

Found: C, 67.95; H, 7.46; N, 4.12.

Example 79



- 90 -

The compound was prepared substantially in accordance with the procedure detailed in Example 62, using the compound of Example 69.

Yield: 93%.

5 IR(KBr): 3421, 2936, 1727 cm^{-1} .

^1H NMR (300MHz, CDCl_3): δ 7.37 (d, $J=3\text{Hz}$, 1H); 7.29 (s, 1H); 6.92 (d, $J=9\text{Hz}$, 1H); 6.91 (dd, $J=3,9\text{Hz}$, 1H); 3.81 (s, 3H); 3.66 (s, 3H); 2.65 (m, 2H); 2.25-2.65 (m, 2H); 1.60-1.80 (m, 5H); 1.38 (s, 3H) and 1.11 (s, 3H).

10 MS(FD): m/e 331(M^+).


Elemental Analysis for $\text{C}_{19}\text{H}_{25}\text{NO}_4$:

Calcd: C, 68.86; H, 7.60; N, 4.23.

Found: C, 69.10; H, 7.83; N, 4.23.

15

Example 80



The compound was prepared substantially in accordance with the procedure detailed in Example 71A, using the compound of Example 69.

Yield: 74%

m.p. 146-148°C.

IR(KBr): 2900, 1725 and 1679 cm^{-1} .

^1H NMR (300MHz, CDCl_3): δ 7.46 (d, $J=3\text{Hz}$, 1H); 7.28 (d, $J=9\text{Hz}$, 1H); 7.14 (dd, $J=3,9\text{Hz}$, 1H); 4.98 (d, $J=13\text{Hz}$, 1H); 3.85 (s, 3H); 3.65 (s, 3H); 3.20 (d, $J=13\text{Hz}$, 1H); 2.35 (m, 1H); 1.70-1.90 (m, 5H); 1.50 (s, 3H); 1.26 (s, 3H).


MS(FD): m/e 397 (M^+).

Elemental Analysis for $\text{C}_{19}\text{H}_{23}\text{BrO}_4$:

Calcd: C, 57.73; H, 5.86;

Found: C, 57.78; H, 6.06.

- 91 -

Example 81

To a solution of 200 mg (0.506 mmol) of the compound of
5 Example 80 in 5 ml of anhydrous MeOH, was slowly added a
solution of NaOMe (prepared in situ by dissolving 34 mg of Na
in 1 ml of anhydrous MeOH). The reaction mixture was
refluxed for 2 hours, cooled and diluted with 30 ml of brine,
under N₂. The resulting layers were separated and the
10 organic layer was dried over Na₂SO₄, filtered and concentrated
to provide an oily resin which was purified using flash
chromatography (gradient eluent of 0-2% EtOAc in CH₂Cl₂).

Yield: 140 mg of a yellowish oil (88%).

IR(CHCl₃) 3009, 2952, 1728 and 1610 cm⁻¹.

15 ¹H NMR (300MHz, CDCl₃): δ 7.57 (d, J=3Hz, 1H); 7.43 (d,
J=9Hz, 1H); 7.15 (dd, J=3,9Hz, 1H); 6.15 (s, 1H); 3.88 (s,
3H); 3.73 (s, 3H); 2.48 (d, J=13Hz, 1H); 2.18-2.29 (m, 1H);
1.71-2.07 (m, 4H); 1.56 (s, 3H) and 1.52 (s, 3H).

MS(FD): m/e 314 (M⁺).


20 Elemental Analysis for C₁₉H₂₂O₄·0.25H₂O:

Calcd: C, 71.54; H, 7.05;

Found: C, 71.71; H, 7.14.

Example 82

25



- 92 -

The compound was prepared substantially in accordance with the procedure detailed in Example 81, using the compound of Example 71A.

IR(CHCl₃): 2952, 1728 and 1653 cm⁻¹.

5 ¹H NMR (300MHz, CDCl₃): δ 8.19 (d, J=8Hz, 1H); 7.57 (m, 2H); 7.41 (s, J=8Hz, 1H); 6.62 (s, 1H); 3.65 (s, 3H); 2.54 (d, J=14Hz, 1H); 2.40 (d, J=13Hz, 1H); 1.90-2.20 (m, 1H); 1.85 (m, 1H); 1.58 (m, 1H); 1.51 (s, 3H) and 1.34 (s, 3H); 1.25 (m, 1H).


10 MS(FD): m/e 284 (M⁺).

Elemental Analysis for C₁₈H₂₀O₃·5H₂O:

Calcd: C, 73.74; H, 7.16;

Found: C, 73.80; H, 7.15.

15

Example 83

The compound was prepared substantially in accordance with the procedure detailed in Example 62, using the compound of Example 81.


20 Yield: 50%.

IR(KBr): 3411, 2950 and 1729 cm⁻¹.

25 ¹H NMR (300MHz, CDCl₃): δ 7.42 (d, J=3Hz, 1H); 7.34 (s, 1H); 7.31 (d, J=9Hz, 1H); 6.96 (dd, J=3, 9Hz, 1H); 6.80 (s, 1H); 3.84 (s, 3H); 3.71 (s, 3H); 2.40 (d, J=13Hz, 1H); 2.13-2.24 (m, 1H); 1.72-2.01 (m, 4H); 1.63 (s, 3H) and 1.40 (s, 3H).

MS(FD): m/e 329 (M⁺).

- 93 -

Example 84

The compound was prepared substantially in accordance with the procedure detailed in Example 81, using the compound of Example 71B.

Yield: 47%.

IR(CHCl₃): 2954, 1728 and 1653 cm⁻¹.


¹H NMR (300MHz, CDCl₃): δ 8.12 (d, J=7.7Hz, 1H); 7.55 (m, 2H); 7.39 (s, J=7.7Hz, 1H); 6.18 (s, 1H); 3.73 (s, 3H); 2.55 (m, 1H); 2.23 (m, 1H); 1.80-2.10 (m, 3H); 1.60 (m, 1H) and 1.55 (s, 6H).

MS(FD): m/e 284 (M⁺).

Elemental Analysis for C₁₈H₂₀O₃:

Calcd: C, 76.03; H, 7.09;

Found: C, 75.77; H, 7.20.

Example 85

The compound was prepared substantially in accordance with the procedure detailed in Example 62, using the compound of Example 82.

Yield: 58.5%.

m.p. 175-180°C.


IR(KBr): 3426, 2932 and 1702 cm⁻¹.

- 94 -

^1H NMR (300MHz, CDCl_3): δ 8.02 (d, $J=7.3\text{Hz}$, 1H); 7.80 (s, 1H); 7.39 (m, 2H); 7.32 (s, 1H); 7.23 (d, $J=8.1\text{Hz}$, 1H); 3.65 (s, 3H); 2.47 (d, $J=13.2\text{Hz}$, 1H); 2.32 (d, $J=14.3\text{Hz}$, 1H); 1.95-2.18 (m, 2H); 1.70 (m, 1H); 1.54 (s, 3H); 1.28 (s, 3H) and 1.23 (m, 1H).

MS(FD)m/e 299 (M^+).

Example 86



The compound was prepared substantially in accordance with the procedure detailed in Example 62, using the compound of Example 84.

Yield: 62.


m.p. 131-134°C.

IR(KBr): 3266, 2955 and 1722 cm^{-1} .

^1H NMR (300MHz, CDCl_3): δ 7.92 (d, $J=7.7\text{Hz}$, 1H); 7.79 (s, 1H); 7.40 (m, 2H); 7.27 (m, 1H); 6.83 (s, 1H); 3.71 (s, 3H); 2.44 (d, $J=12.8\text{Hz}$, 1H); 2.14-2.24 (m, 1H); 1.74-1.98 (m, 4H); 1.64 (s, 3H) and 1.42 (s, 3H).


MS(FD): m/e 299 (M^+).

Example 87



- 95 -

To a stirring solution of 70 mg (0.245 mmol) of the compound of Example 73A in 20 ml of anhydrous THF, was added 32 mg (0.80 mmol) of 60% NaH on mineral oil, under N₂. The resultant mixture was stirred 15 minutes followed by the addition of 0.15 ml (2.25 mmol) of iodomethane, via syringe. The reaction mixture was stirred for 3 hours, quenched by the dropwise addition of H₂O and then partitioned between Et₂O and H₂O. The resultant layers were separated and the organic layer was dried over Na₂SO₄, filtered and concentrated in vacuo to provide a residue which was purified by radial chromatography (eluent of 10% Et₂O in hexanes). Yield: 16 mg of a clear oil (22%). IR(CHCl₃): 3692, 3022, 2950, 1724 and 1678 cm⁻¹. ¹H NMR (300MHz, CDCl₃): δ 7.95 (d, J=7.7Hz, 1H); 7.54 (s, J=8.8Hz, 1H); 7.25 (m, 2H); 3.63 (s, 3H); 2.80 (m, 2H); 2.39 (d, J=7.7Hz, 1H); 1.70-2.05 (m, 5H); 1.43 (s, 3H); 1.28 (s, 3H) and 1.13 (d, J=6.2Hz, 3H). MS(FD): m/e 300 (M⁺). Elemental Analysis for C₁₉H₂₄O₃:
Calcd: C, 75.97; H, 8.05;
Found: C, 75.80; H, 7.96.

Example 88

A mixture of 50 mg (0.165 mmol) of the compound of Example 68, 35 mg (0.165 mmol) of carbobenzyloxyglycine, 35 mg (0.170 mmol) of 1,3-dicyclohexylcarbodiimide (DCC), 2 mg (0.0165 mmol) of 4-dimethylaminopyridine in 25 ml of anhydrous Et₂O was stirred for 16 hours resulting in the formation of a solid. This solid was removed by filtration

- 96 -

and the filtrate was washed sequentially with H₂O, a 5% AcOH solution and brine. The combined organic layers were dried over Na₂SO₄, filtered and then concentrated in vacuo to provide a resin which was purified using flash chromatography (SiO₂, eluent of 20% Et₂O in hexanes).


Yield: 54 mg of a light yellow solid (66%).

IR(KBr): 3330, 2934, 1779, 1725, 1685 cm⁻¹.

¹H NMR (300MHz, CDCl₃): δ 7.70 (s, 1H); 7.36 (m, 8H); 6.20 (s, 2H); 4.26 (d, J=6Hz, 2H); 3.67 (s, 3H); 2.73 (dd, J=3,6Hz, 2H); 2.40 (m, 2H); 1.50-2.00 (m, 5H); 1.35 (s, 3H); 1.28 and (s, 3H).

MS(FD): m/e 494 (M+).

Example 89



The compound was prepared substantially in accordance with the procedure detailed in Example 88, using the compound of Example 68 and N-t-butoxycarbonyl-L-alanine.


Yield: 96%.

IR(CHCl₃): 3444, 2938, 1763, 1714 cm⁻¹.

¹H NMR (300MHz, CDCl₃): δ 7.69 (d, J=2.6Hz, 1H); 7.41 (d, J=8.5Hz, 1H); 7.30 (d, J=2.6Hz, 1H); 5.10 (brm, 1H); 4.55 (brm, 1H); 3.65 (s, 3H); 2.73 (dd, J=3.3, 6.6Hz, 2H); 2.32-2.42 (m, 2H); 1.70-2.20 (m, 5H); 1.55 (d, J=7.0Hz, 3H); 1.47 (s, 6H); 1.43 (s, 3H); 1.35 (s, 3H) and 1.28 (s, 3H).

MS(FD): m/e 474 (M+).

- 97 -

Example 90


A mixture of 100 mg (0.21 mmol) of the compound of
 Example 89 in 2 ml of CH_2Cl_2 was added to 2 ml of a 1:1
 $\text{CH}_2\text{Cl}_2/\text{CF}_3\text{COOH}$ mixture. After stirring for 1 hour, the
 reaction mixture was concentrated in vacuo. The resultant
 residue was concentrated repetitively in Et_2O until a foam
 was obtained.

Yield: 85 mg (83%).

IR(CHCl_3): 2941, 1715, 1711 and 1682 cm^{-1} .

^1H NMR (300MHz, CDCl_3): δ 7.65 (m, 2H); 7.41 (d, $J=8.1\text{Hz}$,
 1H); 4.30 (m, 1H); 3.62 (s, 3H); 2.63 (m, 2H); 2.25-2.40 (m,
 2H); 1.60-1.90 (m, 5H); 1.34 (s, 3H) and 1.24 (s, 3H); 1.22
 (d, $J=7.0\text{Hz}$, 3H).

MS(FD): m/e 374, free base (M^+).


Example 91

To a solution of 550 mg (1.0 mmol) of the compound of
 Example 89 in 10 ml of CH_2Cl_2 , was added 3 ml (39 mmol) of
 CF_3COOH . After stirring for 1 hour, the reaction mixture was
 concentrated in vacuo to provide a foam. This foam was

- 98 -

dissolved in 20 ml of CH_2Cl_2 followed by the addition of 0.17 ml (1.2 mmol) of Et_3N . The resultant layers were separated and the organic layer was washed with H_2O , dried over Na_2SO_4 , filtered and concentrated in vacuo to provide a foam.

5



The compound was prepared substantially in accordance with the procedure detailed in Example 88, using the compound of Example 91A and 230 mg (1.2 mmol) of N-t-butyloxycarbonyl-L-alanine

10

Yield: 255 mg (47%).

IR(KBr): 3334, 2938, 1770, 1725 and 1687 cm^{-1} .

^1H NMR (300MHz, CDCl_3): δ 7.69 (d, $J=3\text{Hz}$, 1H); 7.41 (d,

15

$J=9\text{Hz}$, 1H); 7.29 (d, $J=3\text{Hz}$, 1H); 6.70 (m, 1H); 5.00 (m, 1H); 4.80 (m, 1H); 4.20 (m, 1H); 3.67 (s, 3H); 2.73 (m, 2H); 2.36 (m, 2H); 1.60-1.90 (m, 5H); 1.58 (d, $J=7\text{Hz}$, 3H); 1.45 (s, 9H); 1.38 (d, $J=7\text{Hz}$, 3H); 1.35 (s, 3H) and 1.27 (s, 3H).

MS(FD): m/e 544 (M^+).


Elemental Analysis for $\text{C}_{29}\text{H}_{40}\text{N}_2\text{O}_8 \cdot 0.75\text{H}_2\text{O}$:

20

Calcd: C, 62.40; H, 7.43; N, 5.02;

Found: C, 62.30; H, 7.24; N, 4.77.

Example 92



25

- 99 -

The compound was prepared substantially in accordance with the procedure detailed in Example 90, using the compound of Example 91B.


Yield: 95%..

5 IR(KBr): 2950, 1770 and 1681 cm^{-1} .

^1H NMR (300MHz, CDCl_3): δ 8.17 (brs, 3H); 7.60 (s, 1H); 7.40 (d, $J=2.6\text{Hz}$, 1H); 7.27 (m, 1H); 4.65 (brs, 1H); 4.40 (brs, 1H); 3.70 (d, $J=2\text{Hz}$, 1H); 3.62 (s, 3H); 2.70 (m, 7H); 2.35 (m, 2H); 1.50-1.85 (m, 6H); 1.32 (s, 3H) and 1.23 (s, 3H).

10 MS(FD): m/e 445 free base (M^+).

Example 93



15 The compound was prepared substantially in accordance with the procedure detailed in Example 88, using the compound of Example 68 and N-t-butoxycarbonyl-L-valine.

Yield: 47%. .

IR(KBr): 3377, 2969, 1766, 1724 and 1688 cm^{-1} .

20 ^1H NMR (300MHz, CDCl_3): δ 7.68 (d, $J=2.6\text{Hz}$, 1H); 7.41 (d, $J=8.8\text{Hz}$, 1H); 7.29 (d, $J=2.6\text{Hz}$, 1H); 5.06 (brm, 1H); 4.45 (brm, 1H); 3.65 (s, 3H); 2.74 (dd, $J=3.3, 7.0\text{Hz}$, 2H); 2.30-2.43 (m, 1H); 1.70-1.90 (m, 6H); 1.48 (s, 9H); 1.35 (s, 3H); 1.28 (s, 3H); 1.09 (d, $J=6.6\text{Hz}$, 3H); 1.02 (d, $J=7.0\text{Hz}$, 3H).


25 MS(FD): m/e 502 (M^+).

Elemental Analysis for $\text{C}_{28}\text{H}_{39}\text{NO}_7$:

Calcd: C, 67.04; H, 7.84; N, 2.79;

Found: C, 66.82; H, 7.73; N, 2.58.

- 100 -

Example 94

The compound was prepared substantially in accordance with the procedure detailed in Example 90, using the compound of Example 93.

Yield: 99% yield.

IR(KBr): 3068, 2943, 1758, 1722 and 1668 cm^{-1} .


^1H NMR (300MHz, CDCl_3): δ 7.68 (m, 1H); 7.40 (m, 2H); 4.08 (d, $J=4.8\text{Hz}$, 1H); 3.65 (s, 3H); 2.70 (m, 2H); 2.30-2.40 (m, 2H); 1.70-1.90 (m, 6H); 1.34 (s, 3H); 1.26 (s, 3H); 1.16 (d, $J=2.9\text{Hz}$, 3H) and 1.14 (d, $J=2.9\text{Hz}$, 3H).

MS(FD): m/e free base 402 (M^+).

Elemental Analysis for $\text{C}_{25}\text{H}_{32}\text{NO}_7$:

Calcd: C, 58.25; H, 6.26; N, 2.72;

Found: C, 57.98; H, 6.32; N, 2.64.

Example 95

To a solution of 295 mg (0.98 mmol) of the compound of Example 77 in 5 ml of anhydrous DMF, was added 60 mg (1.50 mmol) of 60% NaH on mineral oil, under N_2 , followed by the addition of 0.18 ml (1.90 mmol) of methyl bromoacetate was added by syringe. The reaction mixture was stirred for 1 hour and then cautiously quenched by the dropwise addition of

- 101 -

brine under N₂. The reaction mixture was partitioned between brine and Et₂O, the resulting layers were separated and the organic layer was dried over Na₂SO₄, filtered and the concentrated in vacuo to provide an oil which was purified using flash chromatography (SiO₂, eluent of 20% Et₂O in hexanes).

Yield: 175 mg of a clear oil (48%).

IR(CHCl₃): 2953, 1737 and 1725 cm⁻¹.

¹H NMR (300MHz, CDCl₃): δ 7.87 (d, J=8Hz, 1H); 7.29 (m, 2H); 7.19 (s, J=8Hz, 1H); 4.75 (s, 2H); 3.76 (s, 3H); 3.69 (s, 3H); 3.17 (dd, J=8,20Hz, 1H); 2.35-2.57 (m, 3H); 1.73-1.85 (m, 1H); 1.44-1.61 (m, 4H); 1.20 (s, 3H) and 0.56 (s, 3H).


MS(FD): m/e 373 (M⁺).

Elemental Analysis for C₂₁H₂₇NO₅:

Calcd: C, 67.54; H, 7.29; N, 3.75;

Found: C, 67.84; H, 7.58; N, 3.89.

Example 96



A mixture of 56.7 mg (0.152 mmol) of the compound of Example 95, 0.2 ml (0.2 mmol) of 1N NaOH and 5 ml of MeOH was stirred at room temperature for 4 days and then diluted to 30 ml with brine and extracted with EtOAc. The layers were separated and the aqueous layer was acidified with 5N HCl and extracted with EtOAc. The combined organic layers were dried over Na₂SO₄, filtered and then concentrated in vacuo.

Yield: 45.7 mg of an amorphous tan resin (84%).

IR(CHCl₃): 3030, 2951 and 1720 cm⁻¹.

¹H NMR (300MHz, CDCl₃): δ 12.75 (brs, 1H); 7.76 (d, J=8Hz, 1H); 7.40 (m, 2H); 7.21 (m, 1H); 4.66 (s, 2H); 3.62 (s, 3H);

- 102 -

3.05 (dd, $J=8,20\text{Hz}$, 1H); 2.47 (m, 3H); 1.60-1.80 (m, 1H);
1.20-1.59 (m, 4H); 1.10 (s, 3H) and 0.42 (s, 3H).


MS(FD): m/e 359 (M^+).

Elemental Analysis for $C_{20}H_{25}NO_5 \cdot 0.25H_2O$:

Calcd: C, 66.05; H, 7.01; N, 3.85;

Found: C, 65.91; H, 7.35; N, 3.61.

Example 97



A mixture of 111.8 mg (0.31 mmol) of the compound of
Example 96, 0.31 ml (0.31 mmol) of 1N NaOH and 10 ml of
anhydrous CH_3CN was sonicated for 30 minutes and then
concentrated in vacuo to provide a residue. This residue was
repetitively concentrated from fresh Et_2O to provide an
amorphous solid.

Yield: 116 mg (98%).


IR(KBr): 3429, 2948, 1725 and 1611 cm^{-1} .

1H NMR (300MHz, $CDCl_3$): δ 7.75 (d, $J=7.4\text{Hz}$, 1H); 7.32 (m,
2H); 7.20 (m, 1H); 4.20 (s, 2H); 3.63 (s, 3H); 3.00 (dd,
 $J=7.7, 19.1\text{Hz}$, 1H); 2.35-2.50 (m, 3H); 1.60-1.80 (m, 1H);
1.40-1.60 (m, 4H); 1.10 (s, 3H) and 0.43 (s, 3H).

MS(FD): m/e 285 ($M^+ - C_2H_2O_3Na$).

- 103 -


Example 98



A mixture of 4.0 g (14.7 mmol) of the compound of Example 70A and 1.2 ml (16.9 mmol) of acetyl chloride in 60 ml of carbon disulfide to a suspension of 2.6 mg (19.5 mmol) of anhydrous aluminum chloride in 100 ml of carbon disulfide, via dropping funnel. The reaction mixture was refluxed for 1 hour and then the carbon disulfide was removed by downward distillation. The resultant residue was cautiously quenched by the addition of 100 ml of 0.2N HCl. The desired compound was extracted using 100 ml of CH₂Cl₂, dried over Na₂SO₄, filtered and then concentrated in vacuo to provide a dark red oil which was purified using flash chromatography (SiO₂, eluent of 20% Et₂O in hexanes).

Yield: 1.7 g of an oil (87% based on recovered starting material).

¹H NMR (300MHz, CDCl₃): δ 7.90 (d, J=4Hz, 1H); 7.75 (d, J=4Hz, 0.5H); 7.63 (d, J=4Hz, 0.5H); 7.37 (d, J=6Hz, 0.5H); 7.10 (d, J=6Hz, 0.5H); 3.70 (s, 1.5H); 3.68 (s, 1.5H); 2.92 (m, 2H); 2.60 (s, 3H); 2.00-2.50 (m, 3H); 1.40-1.98 (m, 6H); 1.29 (s, 1.5H); 1.26 (s, 1.5H); 1.24 (s, 1.5H) and 1.10 (s, 1.5H).




- 104 -

A mixture of 1.7 g (5.4 mmol) of the compound of Example 98A, 1.9 g (5.5 mmol) of 50% 3-chloroperoxybenzoic acid, 18 mg (0.095 mmol) of p-toluene sulfonic acid monohydrate in 25 ml of 1,2-dimethoxyethane was refluxed for 3 hours, under N₂. After cooling, the reaction mixture was diluted with Et₂O and washed sequentially with 10% potassium iodide, 10% sodium thiosulfate, a saturated NaHCO₃ solution and brine, dried over Na₂SO₄, filtered and then concentrated to provide a resin. This resin was dissolved in 25 ml of MeOH and 10 ml of H₂O containing 1.6 g (19.0 mmol) of NaHCO₃. The resultant mixture was refluxed for 1.5 hours, cooled, filtered and concentrated in vacuo to provide a residue. This residue was partitioned between H₂O and Et₂O. The resulting layers were separated and the organic layer was washed sequentially with 1N HCl and brine, dried over Na₂SO₄, filtered and concentrated in vacuo

Yield: 1.55 g (99%).

¹H NMR (300MHz, CDCl₃): δ 6.85 (m, 1H); 6.70 (d, J=6Hz, 1H); 6.55 (dd, J=6Hz, 1H); 3.63 (s, 3H); 2.80 (m, 2H); 1.90-2.30 (m, 3H); 1.40-1.88 (m, 6H); 1.25 (s, 1.5H); 1.20 (s, 1.5H); 1.17 (s, 1.5H) and 1.02 (s, 1.5H).



To a suspension of 1.55 g (5.4 mmol) of the compound of Example 98B and 275 mg (6.87 mmol) of 60% NaH on mineral oil in 50 ml of anhydrous DMF, was added 0.5 ml (7.50 mmol) of iododomethane, under N₂. The reaction mixture was stirred for 1 hour and then cautiously quenched by the dropwise addition of brine. The reaction mixture was partitioned between Et₂O and brine. The resultant layers were separated and the organic layer was dried over Na₂SO₄, filtered and concentrated


- 105 -

in vacuo to provide a residue which was purified using flash chromatography (SiO₂, eluent of 20% Et₂O in hexanes).

Yield: 1.3 g of a clear light yellow oil (88.5% based on recovered starting material).

5 ¹H NMR (300MHz, CDCl₃): δ 7.00 (d, J=6Hz, 1H); 6.82 (m, 1H); 6.70 (m, 1H); 3.80 (s, 3H); 3.70 (s, 3H); 2.80 (m, 2H); 2.00-2.40 (m, 3H); 1.40-1.90 (m, 6H); 1.25 (s, 1.5H); 1.20 (s, 3H); 1.10 (s, 1.5H).


10 Note: The reaction mixture also contained 200 mg of the compound of Example 98A.



15 The compound was prepared substantially in accordance with the procedure detailed in Example 70B, using 1.3 g (4.3 mmol) of the compound of Example 98C. The crude material was purified using flash chromatography (SiO₂, eluent of 20% Et₂O in hexanes).

Yield: 820 mg of an oil (60.5%).

20 ¹H NMR (300MHz, CDCl₃): δ 8.00 (m, 1H); 6.80 (m, 2H); 3.87 (s, 1.5H); 3.85 (s, 1.5H); 3.63 (s, 1.5H); 3.61 (s, 1.5H); 3.01 (dd, J=5, 12Hz, 0.5H); 2.70 (m, 1.5H); 2.40 (m, 2H); 1.40-1.95 (m, 5H); 1.32 (s, 1.5H); 1.30 (s, 1.5H); 1.22 (s, 1.5H); 0.65 (s, 1.5H).




25

- 106 -

The compound was isolated from the reaction mixture described in Example 98D.

Yield: 35.4 mg of an oil.




5

The compound was isolated from the reaction mixture described in Example 98D.

Yield: 150 mg of an oil (10.6%).

¹H NMR (300MHz, CDCl₃): δ 8.17 (d, J=6Hz, 1H); 6.95 (m, 1H); 6.80 (m, 1H); 3.90 (s, 3H); 3.70 (s, 3H); 3.36 (s, 0.5H); 2.50 (m, 1.5H); 1.80-2.10 (m, 1H); 1.42-1.80 (m, 4H); 1.40 (s, 1.5H); 1.20 (s, 1.5H); 1.17 (s, 1.5H); 0.65 (s, 1.5H).

10



15

The compound was obtained by separating the compounds (52 mg) of Example 98E by radial chromatography (eluent of 15% Et₂O in hexanes).

Yield: 20.5 mg (1.1%) (overall yield).


¹H NMR (300MHz, CDCl₃): δ 7.52 (d, J=2Hz, 1H); 7.21 (d, J=6Hz, 1H); 7.10 (dd, J=2.6Hz, 1H); 3.87 (s, 3H); 3.63 (s, 3H); 3.05 (dd, J=4,12Hz, 1H); 2.72 (m, 1H); 2.20-2.50 (m, 2H); 1.80 (m, 2H); 1.40-1.60 (m, 3H); 1.30 (s, 3H) and 0.70 (s, 3H).

20

MS(FD): m/e 316 (M⁺).

25


- 107 -



The compound was prepared substantially in accordance with the procedure detailed in Example 71A, using 975 mg (3.08 mmol) of the compound of Example 98D. The crude material was purified using flash chromatography (SiO₂, eluent of 15% of Et₂O in hexanes).

Yield: 532.6 mg (44%).

¹H NMR (300MHz, CDCl₃): δ 8.03 (d, J=6Hz, 1H); 6.81 (m, 2H); 4.50 (s, 1H); 3.90 (s, 3H); 3.75 (s, 3H); 3.21 (s, 1H); 2.40 (m, 1H); 1.60-2.00 (m, 5H); 1.58 (s, 3H) and 0.60 (s, 3H).




The compound was isolated from the reaction mixture described in Example 98H.

Yield: 465.1 mg of an oil (38%).

¹H NMR (300MHz, CDCl₃): δ 8.00 (d, J=6Hz, 1H); 6.85 (m, 2H); 4.97 (d, J=9Hz, 1H); 3.90 (s, 3H); 3.62 (s, 3H); 3.22 (d, J=9Hz, 1H); 2.30 (m, 1H); 1.80 (m, 5H); 1.48 (s, 3H) and 1.28 (s, 3H).

- 108 -



The compound was prepared substantially in accordance with the procedure of Example 72, using 532.0 mg (1.35 mmol) of the compound of Example 98H.

5 Yield: 280 mg of a pale yellow solid (66%).

m.p. 117-119°C.

IR(CHCl₃): 2942, 1721, 1667 and 1596 cm⁻¹.


10 ¹H NMR (300MHz, CDCl₃): δ 8.04 (d, J=9Hz, 1H); 6.83 (s, 1H); 6.80 (d, J=3Hz, 1H); 3.90 (s, 3H); 3.67 (s, 3H); 3.02 (dd, J=7,19Hz, 1H); 2.72 (dd, J=2,7Hz, 1H); 2.40 (m, 2H); 1.80-1.90 (m, 1H); 1.45-1.65 (m, 4H); 1.31 (s, 3H) and 0.70 (s, 3H).

MS(FD): m/e 316⁺ (M⁺).

Elemental Analysis for C₁₉H₂₄O₄:

15 Calcd: C, 72.13; H, 7.65;

Found: C, 72.43; H, 7.67.



20 The compound was prepared substantially in accordance with the procedure detailed in Example 72, using 465 mg (1.17 mmol) of the compound of Example 98I.

Yield: 328 mg of a clear oil (89%).

IR(CHCl₃): 2942, 1721, 1667 and 1596 cm⁻¹.


25 ¹H NMR (300MHz, CDCl₃): δ 8.01 (d, J=9.2Hz, 1H); 6.85 (s, 1H); 6.81 (d, J=2.6Hz, 1H); 3.90 (s, 3H); 3.66 (s, 3H); 2.70

- 109 -

(m, 2H); 2.30 (m, 2H); 1.60-1.90 (m, 5H); 1.35 (s, 3H) and 1.26 (s, 3H).

MS(FD): m/e 316 (M+).

5

Example 99

The compound was prepared substantially in accordance with the procedure detailed in Example 62, using 465 mg (1.17 mmol) of the compound of Example 98J.

10

Yield: 79%.

IR(CHCl₃): 3500, 2951 and 1719 cm⁻¹.

¹H NMR (300MHz, CDCl₃): δ .81 (d, J=7Hz, 1H); 6.82 (d, J=2Hz, 1H); 6.78 (dd, J=2,7Hz, 1H); 3.83 (s, 3H); 3.70 (s, 3H); 3.07 (dd, J=6,12Hz, 1H); 2.60 (m, 2H); 2.40 (m, 1H), 1.80 (m, 1H); 1.40-1.60 (m, 4H); 1.20 (s, 3H) and 0.60 (s, 3H).

15


MS(FD): m/e 331 (M+).

Elemental Analysis for C₁₉H₂₅NO₄:

Calcd: C, 68.86; H, 7.60; N, 4.23;

Found: C, 68.56; H, 7.44; N, 4.25.

20

Example 100

- 110 -

The compound was prepared substantially in accordance with the procedure detailed in Example 62, using the compound of Example 98K.

Yield: 61%.

5 m.p. 162-165°C.

IR(CHCl₃): 3018, 2951, 1720 and 1600 cm⁻¹.

¹H NMR (300MHz, CDCl₃): δ 7.81 (d, J=6Hz, 1H); 6.82 (m, 3H); 3.90 (s, 3H); 3.70 (s, 3H); 2.62 (d, J=6Hz, 2H); 2.20-2.43 (m, 2H); 1.60-1.90 (m, 5H); 1.40 (s, 3H) and 1.10 (s, 3H).

10 MS(FD): m/e 331 (M+).


Elemental Analysis for C₁₉H₂₅NO₄:

Calcd: C, 68.86; H, 7.60; N, 4.23;

Found: C, 68.79; H, 7.42; N, 4.33.

15

Example 101




The compound was prepared substantially in accordance with the procedure detailed in Example 62, using the compound of Example 98G.

Yield: 90%.


¹H NMR (300MHz, CDCl₃): δ 7.40 (d, J=2Hz, 1H); 7.20 (d, J=6Hz, 1H); 6.93 (dd, J=2,6Hz, 1H); 3.82 (s, 3H); 3.70 (s, 3H); 3.10 (dd, J=5,13Hz, 1H); 2.50-2.63 (m, 2H); 2.1 (d, J=8Hz, 1H); 2.30 (m, 1H); 1.20-1.40 (m, 4H); 1.20 (s, 3H) and 0.60 (s, 3H).

MS(FD): m/e 331 (M+).

- 111 -


Example 102

The compound of Example 70A (14.0 g) was subjected to
5 flash chromatography (SiO_2 , eluent of hexanes) to provide
12.5 g of an oil. This oil was redissolved in hexanes and
allowed to stand for 16 hours in a refrigerator which
resulted in the formation of a solid. This solid was
isolated by filtration (3.9 g, 14.3 mmol) and 1.0 g was
10 dissolved in 100 ml of triethylene glycol dimethyl ether
containing 1.0 g of 10% Pd/C and refluxed for 6 hours, under
 N_2 . After cooling, the mixture was filtered over celite, and
the filtrate was partitioned between EtOAc and H_2O . The
resultant layers were separated and the organic layer was
15 dried over Na_2SO_4 , filtered and concentrated in vacuo to
provide a liquid. This liquid was diluted with H_2O which
resulted in the formation of a solid. This solid was
isolated by filtration, dissolved in hexanes and allowed to
crystallize at room temperature.
20 Yield: 297 mg (1.09 mmol).




The compound was prepared substantially in accordance
with the procedure detailed in Example 98A, using the
25 compound of Example 102A.
Yield: 330 mg (98%).

- 112 -




The compound was prepared substantially in accordance with the procedure detailed in Example 98B, using the compound of Example 102B.

Yield: 300 mg (99%).



The compound was prepared substantially in accordance with the procedure detailed in Example 98C, using the compound of Example 102C.

Yield: 239 mg (76%).



The compound was prepared substantially in accordance with the procedure detailed in Example 70B, using the compound of Example 102D.

Yield: 153 mg of a white solid (61%).

m.p. 107-108°C.

- 113 -

IR(KBr): 2943, 1724, 1681 and 1591 cm^{-1} .

^1H NMR (300MHz, CDCl_3): δ 8.06 (d, $J=8.5\text{Hz}$, 1H); 6.88 (d, $J=2.2\text{Hz}$, 1H); 6.83 (dd, $J=2.2, 8.5\text{Hz}$, 1H); 3.84 (s, 3H); 3.70 (s, 3H); 3.19 (m, 1H); 2.95 (dd, $J=3.3, 18.0\text{Hz}$, 1H); 2.33 (brd, $J=11.0\text{Hz}$, 2H); 2.05 (m, 2H); 1.70 (m, 1H); 2.57 (m, 1H); 1.25 (s, 3H); 1.12 (m, 1H) and 1.10 (s, 3H).


MS(FD): m/e 316 (M^+).

Elemental Analysis for $\text{C}_{19}\text{H}_{24}\text{O}_4$:

Calcd: C, 72.13; H, 7.65;

Found: C, 72.13; H, 7.45.

Example 103



The compound was prepared substantially in accordance with the procedure detailed in Example 62, using the compound of Example 102E. The crude material was purified by recrystallization from Et_2O /hexanes.

Yield: 84%.

m.p. 172-174°C.

IR(KBr): 3286, 2959, 1721 and 1603 cm^{-1} .

^1H NMR (300MHz, CDCl_3): δ 7.93 (d, $J=6\text{Hz}$, 1H); 6.84 (d, $J=2\text{Hz}$, 1H); 6.78 (dd, $J=2, 6\text{Hz}$, 1H); 3.80 (s, 3H); 3.65 (s, 3H); 3.43 (dd, $J=3, 12\text{Hz}$, 1H); 3.10 (m, 1H); 2.30 (d, $J=8\text{Hz}$, 2H); 2.00 (m, 1H); 1.70 (m, 2H); 1.50 (m, 1H); 1.30 (s, 3H); 1.10 (m, 1H) and 1.00 (s, 3H).

MS(FD): m/e 331 (M^+).

Elemental Analysis for $\text{C}_{19}\text{H}_{25}\text{NO}_4$:

Calcd: C, 68.86; H, 7.60; N, 4.23;

Found: C, 69.09; H, 7.55; N, 4.38.

- 114 -

As noted above, the compounds of the present invention are useful for inhibiting an envelope virus that undergoes hemagglutinin-mediated fusion with a host cell. An embodiment of the present invention is a method of treating or preventing a viral infection where the virus is an envelope virus that undergoes hemagglutinin-mediated fusion with a host cell which comprises administering to a virus infected cell, a cell susceptible of infection or a mammal in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. Another embodiment of the present invention is a method of treating or preventing the symptoms associated with a viral infection comprising administering to a mammal in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. A further embodiment of the present invention is a method of inhibiting viral replication comprising administering to a virus-infected cell, a cell susceptible to infection or a mammal in need thereof, an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.

The term "effective amount" as used herein, means an amount of a compound of the present invention which is capable of inhibiting the hemagglutinin-mediated viral fusion with the host cell. The viral inhibition contemplated by the present method includes both therapeutic and prophylactic treatment, as appropriate. The specific dose of compound administered according to this invention to obtain therapeutic and/or prophylactic effects will, of course, be determined by the particular circumstances surrounding the case, including, for example, the compound administered, the route of administration, the condition being treated and the individual being treated. A typical daily dose (administered in single or divided doses) will contain a dosage level of from about 0.01 mg/kg to about 50 mg/kg of body weight of an active compound of this invention. Preferred daily doses generally will be from about 0.05 mg/kg to about 20 mg/kg and ideally from about 0.1 mg/kg to about 10 mg/kg. The

- 115 -

compounds can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular and intranasal.

5 The compounds can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular and intranasal. The compounds of the present invention are preferably formulated prior to administration. Therefore, another embodiment of the present invention is a pharmaceutical formulation comprising an
10 effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent or excipient therefor.

The active ingredient in such formulations comprises
15 from 0.1% to 99.9% by weight of the formulation. By "pharmaceutically acceptable" it is meant that the carrier, diluent or excipient is compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

20 The present pharmaceutical formulations are prepared by known procedures using known and readily available ingredients. In making the compositions of the present invention, the active ingredient will usually be admixed with a carrier, or diluted by a carrier, or enclosed within a
25 carrier which may be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent, it may be a solid, semi-solid or liquid material which acts as a vehicle, excipient or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills,
30 powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions,
35 sterile packaged powders and the like.

- 116 -

The following experiments were carried out to demonstrate the ability of the compounds of the present invention to inhibit influenza.

5

In vitro CPE/XTT Assay

MDCK cells were dispersed in a microtiter plate (96 wells) at 10,000 cells per well with Medium 199 containing Earl's balanced salt solution (EBSS), 1% fetal bovine serum (FBS), penicillin (100 units/ml) and streptomycin (100 µg/ml). After standing overnight at 37°C in a carbon dioxide (CO₂) incubator, the MDCK cells were infected with ~0.1 moi (multiplicity of infection) of influenza virus (i.e. A/Kawasaki/89 or B/Hong Kong and B/Great Lakes) at 0.03 moi. After allowing the virus to adsorb to the cells for 1-2 hours, medium containing serial dilutions of drug or medium alone was added to the wells. The resultant mixtures were incubated for 2-3 days (until extensive cpe was apparent in medium alone wells). The antiviral effect of a test compound was assessed by performing the following XTT assay.

A fresh solution (0.4 mg/ml) of XTT [2,3-bis(methoxy-4-nitro-5-sulphophenyl)-2H-tetraazolum-5-carboxanilide, inner salt, sodium salt] in warm medium without FBS was prepared. For each 5 ml of the XTT solution, 25 µl of 5mM PMS (phenazine methosulfate) in phosphate buffer saline was added. After withdrawing the cultured supernatant, 100 µl of the freshly prepared XTT/PMS mixture was added to each of the microtiter wells. The wells were then incubated at 37°C (under CO₂) for 3-4 hours or until color change is prominent. The absorbance at 450 nm (ref. 650 nm) was read in a spectrophotometer. The concentration of test compound required to cause 50% cytotoxic effect (TC₅₀) relative to a control with no drug and no virus present and which inhibits the development of virus cytopathic effect (cpe) by 50% (IC₅₀) or 90% (IC₉₀) was determined from the linear portion of each dose response curve.

Using this CPE/XTT assay, the IC₅₀ of the compounds of formula I was determined to be in the range of 0.01-32.0 µg/ml

- 117 -

for influenza A/Kawasaki/89 and in the range of 0.7-97.0 µg/ml for influenza B/Great Lakes.

Plaque Reduction Assay

5 Susceptible MDCK cells were grown in 6 well tissue culture treated cluster plates at 1×10^6 cells/well in Minimum 199 with 1 percent fetal bovine serum, penicillin (100 units/ml) and streptomycin (100 µg/ml). After overnight incubation at 37°C, the growth medium was removed and 0.2
10 ml/well of an appropriate dilution of virus was added. After adsorption for 1-2 hour at room temperature, the infected cell sheet was overlaid with equal parts of 1.5% sterile agarose solution and a twofold concentration of medium 199 (with 2% fetal bovine serum, 100 units/ml of penicillin and
15 100 µg/ml streptomycin) containing varying concentrations of compounds.


 The compounds were dissolved in DMSO at a concentration of 20 mg/ml and an aliquot was diluted to the desired concentration in DMSO and then added to the agar medium
20 mixture. The plates were incubated in a CO₂ incubator at 37°C until the DMSO control wells contained plaques of optimal size. Then, a solution containing 10 percent formalin and 2 percent sodium acetate was added to each well to inactivate the virus and fix the cell sheet to the plastic
25 surface. The fixed cell sheets were stained with 0.5 percent crystal violet and the plaques were counted. Results from duplicate wells at each concentration were averaged and compared with DMSO control wells. The inhibition of plaque formation by 50 or 90 percent (IC₅₀ or IC₉₀) was calculated
30 from the linear region of the inhibition concentration curve using the method of Reed and Muench, Am. J. Hyg., vol. 27, pages 493-497 (1958).

 Using the plaque reduction assay, the IC₅₀ of the compounds of formula I was determined to be in the range of
35 0.006-100.0 µg/ml for influenza A/Kawasaki and in the range of 1.47-100.0 µg/ml for influenza B/Great Lakes.

- 118 -

Claims

1. A pharmaceutical formulation comprising a compound of formula I:



I

wherein:

R is hydrogen or R and R⁶ combine to form a bond;

R⁰ and R¹ are independently hydrogen, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy(C₁-C₆ alkyl), sulfhydryl, sulfamyl, -SO₂-Cl, -S-C(O)-N(CH₃)₂, amino, C₁-C₄ alkylamino, di(C₁-C₄ alkyl)amino, C₁-C₄ alkylsulfonylamino, di(C₁-C₄ alkylsulfonyl)amino -X⁰-O-C(O)-C₁-C₄ alkyl, -O-(X¹)_i-X², -C(O)-X³, -N-C(O)-R² or -O-R³;

X⁰ is a bond or divalent(C₁-C₆ alkyl);

X¹ is an amino acid;

X² is hydrogen or an amino protecting group;


i is 1, 2 or 3;

X³ is C₁-C₆ alkyl, C₁-C₆ alkoxy, halo(C₁-C₆ alkyl), hydroxy(C₁-C₆ alkyl) or phenyl;

R² is C₁-C₄ alkyl, C₁-C₄ alkoxy, halo(C₁-C₄ alkyl), hydroxy(C₁-C₄ alkyl), phenyl, p-methoxy-phenyl, p-fluoro-phenyl, naphthyl, pyridyl, piperidinyl, thiazolyl, oxazolyl, thienyl, furyl, tetrahydrofuryl or cyclohexyl;

R³ is C₁-C₆ alkenyl, -CH₂-R^{3a}, -C(O)-R^{3b}, -C(S)-R^{3c}, -C(CH₃)₂C(O)NH₂, phenyl or a group of the formula:

- 119 -



R^{3a} is phenyl, p-fluorophenyl, pyridyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, N-(C₁-C₄ alkoxy carbonyl)piperidinyl, N-(trifluoromethyl)-piperidinyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, isooxazolyl, quinolyl, isoquinolyl, thienyl, furyl, tetrahydrothienyl, tetrahydrofuryl, cyclohexyl, cyclopentyl, cyclopropyl or naphthyl;

R^{3b} is pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, N-(C₁-C₄ alkoxy carbonyl)piperidinyl, N-(trifluoromethyl)piperidinyl, benzyloxy, pyridylmethoxy, C₁-C₆ alkoxy, halo(C₁-C₄ alkoxy), amino, C₁-C₄ alkylamino or di(C₁-C₄ alkyl)amino;

R^{3c} is amino, C₁-C₄ alkylamino or di(C₁-C₄ alkyl)amino;

R^{3d} is oxygen, hydroximino, hydrazino or =CHZ;

Z is hydrogen, C₁-C₄ alkyl, halogen, di(C₁-C₄ alkyl)amino, C₁-C₄ alkoxy carbonyl, carbamoyl(C₁-C₄ alkyl), N-(C₁-C₄ alkyl)carbamoyl or N,N-di(C₁-C₄ alkyl)carbamoyl;

R^{3e} is hydrogen, nitro or trifluoromethyl;

X is a bond or -(CH₂)-;

R^4 is hydrogen, hydroxy, amino, C₁-C₄ alkylamino, di(C₁-C₄ alkyl)amino, C₁-C₄ alkoxy, =O, -O-S(CH₃)₂C(CH₃)₃, C₂-C₆ alkanoyloxy, N-(C₂-C₆ alkanoyl)amino, =N-R⁵ or R^4 and R^6 combine to form a bond;

R^5 is hydroxy, amino, C₁-C₄ alkylamino, di(C₁-C₄ alkyl)amino, C₁-C₄ alkoxy, pyridylmethoxy, benzyloxy, piperazinyl, N-(methyl)piperazinyl or -O-CH₂-C(O)-R^{5a};

R^{5a} is hydroxy or C₁-C₄ alkoxy;

R^6 is hydrogen, halo, C₁-C₄ alkyl or =O;

R^7 is hydrogen or C₁-C₄ alkyl;

R^8 is hydroxy, halo, C₁-C₆ alkoxy, pyrrolidinyl, piperidinyl, piperazinyl, 4-methyl-piperazinyl, morpholinyl or -N(R⁹)-R¹⁰;

- 120 -

R^9 is hydrogen or methyl;

R^{10} is -(divalent C_1 - C_6 alkyl)- R^{10a} ;

R^{10a} is pyridyl,

with the proviso that R^6 cannot combine with both R^4 and R to form a bond;

or a pharmaceutically acceptable salt thereof;

associated with one or more pharmaceutically acceptable carriers, excipients or diluents therefor.

2. A pharmaceutical formulation according to claim 1 where the compound is one wherein:

R^0 is hydrogen, hydroxy, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy(C_1 - C_6 alkyl), $-X^0-O-C(O)-C_1-C_4$ alkyl, $-O-(X^1)_i-X^2$, $-C(O)-X^3$ or $-O-R^3$;

R^1 is hydrogen, hydroxy, C_1 - C_6 alkoxy, sulfhydryl, sulfamyl, $-SO_2-Cl$, amino, di(C_1 - C_4 alkylsulfonyl)amino, $-C(O)-X^3$, $-N-C(O)-R^2$ or $-O-R^3$;

X^0 is a bond or divalent(C_1 - C_6 alkyl);

X^1 is an amino acid;


X^2 is hydrogen or an amino protecting group;

i is 1 or 2;

X^3 is C_1 - C_6 alkyl;

R^2 is hydroxy(C_1 - C_4 alkyl);

R^3 is C_1 - C_6 alkenyl, $-CH_2-R^{3a}$, $-C(O)-R^{3b}$, $-C(S)-R^{3c}$, $-C(CH_3)_2C(O)NH_2$ or a group of the formula:



R^{3a} is phenyl, p-fluorophenyl, pyridyl, piperidinyl, piperazinyl or morpholinyl;

R^{3b} is piperidinyl, piperazinyl, morpholinyl, N-(C_1 - C_4 alkoxy carbonyl)piperidinyl, N-(trifluoromethyl)piperidinyl, halo(C_1 - C_4 alkoxy) or di(C_1 - C_4 alkyl)amino;

R^{3c} is di(C_1 - C_4 alkyl)amino;

- 121 -

R^{3d} is oxygen or hydroximino;
R^{3e} is hydrogen, nitro or trifluoromethyl;
X is a bond;
R⁴ is hydrogen, hydroxy, amino, =O, C₂-C₆ alkanoyloxy,
5 =N-R⁵, -OSi(CH₃)₂ or R⁴ and R⁶ combine to form a bond;
R⁵ is hydroxy, amino, di(C₁-C₄ alkyl)amino, C₁-C₄ alkoxy,
pyridylmethoxy, N-(methyl)piperazinyl or
-O-CH₂-C(O)-R^{5a};
R⁶ is hydrogen, chloro, bromo, methyl or =O;
10 R⁷ is hydrogen or methyl;
R⁸ is hydroxy, chloro, methoxy, 4-methylpiperazinyl or
-N(R⁹)-R¹⁰;
R⁹ is hydrogen;
R¹⁰ is -CH₂-R^{10a}; and
15 R^{10a} is pyridyl.

3. A pharmaceutical formulation according to claim 2
where the compound is one wherein:
R⁰ is hydrogen, hydroxy, C₁-C₆ alkoxy, -O-(X¹)_i-X²,
20 -X⁰-O-C(O)-C₁-C₄ alkyl or -O-R³;
R¹ is hydrogen, hydroxy, C₁-C₆ alkoxy or -O-R³;
X⁰ is a bond;
X¹ is an amino acid;
X² is hydrogen or an amino protecting group;
25 i is 1 or 2;
R³ is C₁-C₆ alkenyl, -CH₂-R^{3a} or -C(O)-R^{3b};
R^{3a} is p-fluorophenyl or pyridyl;
R^{3b} is piperidinyl;
R⁴ is hydrogen, hydroxy, =O or =N-R⁵;
30 R⁵ is hydroxy, dimethylamino or N-(methyl)piperazinyl;
R⁶ is hydrogen, bromo or =O;
R⁷ is methyl; and
R⁸ is methoxy.

35 4. A pharmaceutical formulation according to claim 3
where the compound is one wherein:
R is hydrogen;

- 122 -

R^0 is hydrogen, hydroxy, C_1 - C_4 alkoxy, $-O-(X^1)_i-X^2$,
-O-C(O)methyl or $-O-R^3$;

R^1 is hydrogen, hydroxy, C_1 - C_4 alkoxy or $-O-R^3$;

X^1 is glycine, alanine or valine;

5 X^2 is hydrogen, t-butoxycarbonyl or benzyloxycarbonyl;

R^4 is $=O$ or $=N-R^5$;

R^5 is hydroxy;

R^6 is hydrogen.

10 5. A compound of formula I, or a pharmaceutically acceptable salt thereof, as described in any of claims 1 to 4, for use as a pharmaceutical.

15 6. A compound of formula I, or a pharmaceutically acceptable salt thereof, as described in any of claims 1 to 4, for use as an antiviral.

20 7. A method of inhibiting an envelope virus that undergoes hemagglutinin-mediated fusion with a host cell which comprises administering to a virus-infected cell, a cell susceptible of infection or a mammal in need thereof, an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.

25 8. A method as claimed in claim 7 where the virus is influenza, bovine diarrheal, hepatitis C or tick borne encephalitis virus.

30 9. A method of treating or preventing a viral infection where the virus is an envelope virus that undergoes hemagglutinin-mediated fusion with a host cell which comprises administering to a virus-infected cell, a cell susceptible of infection or a mammal in need thereof, an effective amount of a compound of formula I or a
35 pharmaceutically acceptable salt thereof.

- 123 -

10. A method as claimed in claim 9 where the virus is influenza, bovine diarrhea, hepatitis C or tick borne encephalitis virus.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/07525

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/215

US CL :514/510

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/510

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| A | US 3,668,223 A (JONES) 06 JUNE 1972, see entire document, especially column 2. | 1-10 ,in part |

☐

Further documents are listed in the continuation of Box C.

☐

See patent family annex.

| | |
|--|---|
| * Special categories of cited documents: | *T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| *A document defining the general state of the art which is not considered to be of particular relevance | *X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| *E earlier document published on or after the international filing date | *Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *G document member of the same patent family |
| *O document referring to an oral disclosure, use, exhibition or other means | |
| *P document published prior to the international filing date but later than the priority date claimed | |

Date of the actual completion of the international search

11 AUGUST 1997

Date of mailing of the international search report

03 SEP 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

R. W. RAMSUER

Telephone No. (703) 308-1255

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/07525

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 1-10, in part
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Please See Extra Sheet.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/07525

BOX I. OBSERVATIONS WHERE CLAIMS WERE FOUND UNSEARCHABLE

2. Where no meaningful search could be carried out, specifically:

The multitude of variables and their permutations and combinations (e.g. R,R0,R1,R2,R3,R4,R3a,R3b,X0,X1,X2,X3, etc.) result in claimed subject matter that is so broad in scope that it is rendered virtually incomprehensible and thus no meaningful search can be given. Note also that the claimed subject matter lacks a significant structural element qualifying as the special technical feature that clearly defines a contribution over the art. The subject matter claimed contains an octahydro methyl phenanthrene group which does not define a contribution over the prior art. Therefore, the first discernible invention i.e. the method of inhibiting influenza virus in a virus infected cell by administering thereto the compound of Example 1B, has been searched.